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91.1. Cervical cancer incidence and mortality
Worldwide, cervical cancer is the second most common female 
malignancy, diagnosed in 500,000 women each year, while 275,000 
die from it.1 Without prevention, the peak incidence occurs at a 
relatively young age, between 40-55 years,1, 2 when women are 
still active on the labour market and have young children. 
While cervical cancer is the leading cancer-related cause of 
death1 and the second most common cancer in women in devel-
oping countries (incidence rates ≥30 per 100,000),3 it became 
much less common in developed countries in the recent decades. 
In the Netherlands, the incidence and mortality have been 
decreasing for decades (Figure 1-1). In 2003, cervical cancer was 
newly diagnosed in 584 women (World standardized incidence 
rate (WSR): 4.9 per 100,000 women) and 214 women died from 
it (WSR: 1.4 per 100,000 women).4 
Inter-country differences in cervical cancer incidence are 
caused by differences in determinants and in access to preven-
tive measures. The prevalence of the Human Papillomavirus (HPV) 
infection, the necessary factor in the development of cervical can-
cer,5 is generally higher in developing countries.6 Differences in 
the host factor, e.g. more common malnourishment and the prev-
alence of other infections in the developing countries,7 may also 
play a role. These countries typically do not offer population-wide 
cervical cancer screening facilities, which require a high level of 
organization and adequate health care resources. 
1.2. The epidemiology of Human 
Papillomavirus infection and its role in the 
aetiology of cervical cancer
The association between HPV and cervical cancer is among the 
strongest ever observed for human cancer, and is considered 
causal but not suffi cient for developing cervical cancer.3, 5, 8 
The usual mode of transmission of anogenital types of HPV is 
through sexual contact.3 HPV infection is most common when 
women are most sexually active. For example, HPV can be 
detected in 15-25% of women below age 30.9-13 After age 30, 
the prevalence decreases to 3%-7%.9, 12, 14-17 In some countries, 
a second peak around age 50 has been described, though it is 
much lower than among women below age 30.16, 18-21 It is esti-
mated that 50-80% of women will be infected with HPV at least 
once in their lifetime.22 
As the immune system is usually capable of clearing the 
HPV without any medical intervention,25-28 most HPV infections 
are transient. Eventually only up to 20% of infections cause 
preinvasive cervical neoplasia.29 While the lesions are still pre-
invasive, HPV clearance leads to spontaneous regression of the 
majority of these lesions. Invasive cancer, on the other hand, 
is a rare consequence of an infection with one or more of the 
high-risk, or oncogenic, types of HPV.5, 8, 30 Oncogenic HPV types 
are defi ned as those that could be identifi ed in cervical cancer: 
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 
82, and probably also 26, 53, and 66.31 
1.3. Secondary cervical cancer prevention
Cervical cancer is preventable. It is preceded by a long asymp-
tomatic but screen-detectable preinvasive stage lasting more 
than 10 years on average32-34 which is identifi able as cervical 
intraepithelial neoplasia grades 1, 2 or 3 (CIN 1-3), ranked by 
severity of the abnormality.35, 36 The majority of these lesions, 
about 75%, would never progress to cancer in absence of treat-
ment.32, 37 Because it is at present not possible to distinguish 
between the progressive and non-progressive lesions, women 
with preinvasive lesions, espe-
cially the high-grade ones (usu-
ally defi ned as CIN 2+), are usu-
ally treated. Outpatient CIN 
treatment has a very high suc-
cess rate. It reduces the risk of 
progression to cancer by 95%.38 
In the past decades, the pre-
dominant mode of cervical can-
cer prevention has been second-
ary prevention – screening for 
preinvasive lesions. Historically, 
the most important screening 
tool has been cytology using 
the Pap smear, whereas recently 
also HPV testing is gaining in 
importance. 
The Pap smear
The presence of cervical abnor-
malities is primarily screened for 
with a Pap smear. The Pap smear 
was developed in the 1940’s39 
and was adopted in developed 
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countries in the subsequent decades as a mass screening tool. 
The Pap smear is a cytological sample of exfoliated cells col-
lected directly from the cervix uteri. Primarily taken by a nurse, 
a general practitioner or a gynaecologist, it is thereafter evalu-
ated under a microscope by a cytotechnician or a pathologist. 
Subsequently, cytologycally identifi ed morphological changes 
are diagnostically confi rmed by a gynaecologist applying col-
poscopy-guided histological sampling, which is evaluated in a 
laboratory by a pathologist. Table 1-1 relates several commonly 
used cytological classifi cations40 with those for the histologi-
cal outcomes. 
The Pap smear induces a certain degree of over-treatment, 
as a proportion of lesions that are detected and treated would 
spontaneously regress.41 There has been no randomized con-
trolled trial to assess the decrease in incidence and mortality 
from cervical cancer due to screening. Several important epi-
demiologic studies nevertheless observed that the widespread 
introduction of Pap smear screening accelerated the already 
existing downward trends in the incidence and the mortality 
from cervical cancer.42, 43 These shifts in trends were strongest 
in countries with more intensive screening schedules, and in the 
age groups that were targeted by the programmes (as opposed 
to younger and older women in whom very little screening was 
done). 
New technologies: the HPV test
The identifi cation of the causal role of the HPV in the devel-
opment of cervical abnormalities allows secondary prevention 
through HPV detection, as well primary prevention through 
HPV vaccination. Much effort has been invested into improv-
ing the tools for HPV detection.44 At present, the most widely 
used types of HPV tests are the Hybrid Capture II (HC II) and 
the Polymerase Chain Reaction (PCR) tests. Compared to the 
Pap smear, the HPV test detects an (active) HPV infection. The 
currently available HPV tests offer better test reproducibility 
and sensitivity, but are less specifi c for progressive conditions, 
and at present more expensive.45 In recent years, the accumu-
lated epidemiological evidence and the technological advance-
ments have fuelled a discussion on whether and in what way 
the HPV test could or should complement or substitute the Pap 
smear.45-47 To date, three potential applications of HPV testing 
to enhance cervical cancer screening and diagnosis have been 
proposed: in primary screening, in triage of low-grade cytologi-
cal abnormalities, and in follow-up after treatment of preinva-
sive lesions.45, 48 However, because HPV testing has long been an 
emerging technology, high-quality data with long-term follow-
up is just beginning to become available.
1.4. Cervical cancer screening in the 
Netherlands
In the Netherlands, Pap-smear screening became widespread 
in the 1970’s when 3 pilot screening programmes were started 
in Nijmegen, Rotterdam and Utrecht. Similar programmes were 
soon adopted in other regions but were stopped by mid-1980’s 
when decentralized programmes were introduced instead. It was 
soon established that these were not performing well: the cover-
age was unsatisfactory, and the burden of false-positive screen-
ing results was high.51-53 In 1991, the Ministry of Health called 
for the programme to undergo substantial changes as a con-
dition for centralized fi nancing.54 Several professional groups Ta
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involved in screening (pathologists, general practitioners, 
gynaecologists, cancer registries, municipal health authorities, 
epidemiologists) debated the possible alternatives. As part of 
this process, a comprehensive ex-ante cost-effectiveness analy-
sis performed by the Department of Public Health of the Eras-
mus MC (before 2003 Erasmus University)55 played an important 
role in the reconsideration of the age range and the screening 
interval. In 1993, the Dutch Health Insurance Council issued 
the main programme guidelines56 that were followed in 1996 by 
the national guidelines for general practitioners,57 in 1997 for 
pathologists49 (revised in 2006)58 and in 1998 for gynaecolo-
gists.59 Screening according to the new guidelines, described in 
detail together with the outcomes in Chapter 2 of this thesis, 
was implemented nationally in 1996 at an estimated yearly cost 
of approximately €30 million.60 
1.5. The role of programme evaluation in the 
Netherlands
In contrast with the situation before 1996, regional and 
national monitoring and evaluation became a component of the 
programme. Regular monitoring is required both to identify and 
solve specifi c bottlenecks that are impeding an effi cient and 
high-quality service delivery, and more generally to ensure that 
the public fi nances continually invested in the programme are 
spent in a responsible way. 
Throughout this period, national monitoring and evaluation 
has been performed by the Department of Public Health of the 
Erasmus MC in Rotterdam. Several periodic national reports have 
been published: regarding the years 199461 (the last year before 
the stepwise implementation of the new guidelines, serving as 
the base to measure subsequent changes), 1996 and 1997,62 
1998-2001,60 2002,63, 64 2003,63, 65 2004,66 200567 and 2006,68 as 
well as an ex-post cost-effectiveness analysis,69 alongside sev-
eral international publications on specifi c topics.41, 70-80 
The data source for the national evaluation
The data used for the evaluation was periodically retrieved 
from the Dutch nation-wide network and registry of histo- and 
cytopathology (PALGA). From 1990 onwards PALGA in principle 
achieved national coverage of pathology laboratories.81 Rather 
than the evaluation of screening activities, its primary purpose 
was to support physicians in making everyday treatment deci-
sions for their patients. As such, especially for the earlier reg-
istration years, it does not allow the evaluation of all aspects 
of the screening programme. Nevertheless, it offers information 
on all cytology and histology testing performed, regardless of 
the technique, setting and reason. Because for every test reg-
istered in PALGA the woman’s (coded) identifi cation, the date, 
and the topographic and morphologic codes (Thesaurus-compat-
ible codes for histologic tests, and CISOE-A codes for smears49) 
are known, screening and diagnostic histories can be observed 
for all women with at least one test performed on their cervix 
uteri. Moreover, the use of PALGA for cervical cancer screening 
evaluation has increased and eventually led to improvements 
of the registry for this purpose. Only few other countries have 
established a similarly comprehensive data source that enables a 
comprehensive evaluation of the screening activity.82 
In a collaboration between Prismant (the PALGA data man-
ager) and the Department of Public Health of the Erasmus MC, 
all PALGA records with cervix uteri as topography are retrieved 
and interpreted within the so-called PALEBA project.83 At pres-
ent, the PALEBA/PALGA fi le contains the data retrieved until 
31st March 2007, with almost 20 million records for at least 5 
million screened women, and offers 17 years of follow-up with 
complete coverage. 
1.6. Research questions in the thesis
The goal of this thesis is to give a comprehensive overview of the 
– short-term as well as long-term – outcomes of the changes in 
cervical cancer screening in the Netherlands since 1996. Other 
goals were to evaluate the need for continued cervical cancer 
screening in women with several consecutive negative smears 
by age 50, and to explore the possible role of HPV testing as a 
future technique for cervical cancer prevention. The research 
can be summarized as addressing the following 5 research ques-
tions.
1. What were the short-term effects of changes 
in screening programme protocols and guidelines 
since 1996?
The changes concerned both the medical and the organisational 
aspects. Their goal was to streamline the screening organisa-
tion and process, and to improve the balance between screen-
ing effectiveness, negative side effects, and costs. These goals 
are refl ected in several short-term screening process indicators: 
the screening coverage, the proportion of women screened with 
positive results, the completeness of follow-up, and the yearly 
number of smears made. In Chapter 2, the changes in these 
indicators were evaluated when the fi rst 5-year screening round 
under the new protocols and guidelines was completed. 
2. Did the sensitivity of the Pap smear decrease 
after a broader defi nition of a negative smear? 
In population-based screening of apparently healthy individu-
als, test specifi city, i.e. the proportion of truly non-diseased 
persons who are so identifi ed by the screening test,84 should be 
high.85 This was not the case in the Netherlands before 1996, 
when in each screening round more than 10% of all smears were 
classifi ed as abnormal.51 In response, the threshold for minimum 
relevant smear abnormality (requiring short-term follow-up) 
was elevated so that infl ammation without concurrent dysplasia 
was no longer classifi ed as abnormal.49 This caused a drop in the 
frequency of smears classifi ed as abnormal by about 80%.86 A 
higher cut-off point for test positivity will decrease the sensitiv-
ity of the screening test, i.e. the proportion of diseased persons 
in the population who have a positive screening test.84 However, 
the sensitivity is very complex to estimate empirically87 because 
the majority of the screened population is screened with nega-
tive results and is not subjected to subsequent diagnostic test-
ing – their true disease status is therefore unknown. For this 
reason, test sensitivity is in practice judged through the inter-
val cancer incidence rate, i.e. the incidence of cervical cancer 
after a negative smear. The observed change in this rate for the 
Dutch cervical cancer screening programme since 1996 is pre-
sented in Chapter 3.
3. Can screening be ceased for women with several 
negative smears by age 50? 
Cervical cancer screening is an effective, yet compared to e.g. 
breast cancer screening a relatively costly preventive health 
Matejka BW.indd   11 31-10-2008   15:27:58
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intervention; it also induces anxiety in women.43, 88, 89 Iden-
tifi cation and exclusion of subgroups at negligible risk create 
an opportunity to decrease this burden without measurably 
decreasing the overall effectiveness of the screening programme. 
Several authors argued that this is the case with well-screened 
women who at the age of around 50 had several consecutive 
negative smears.90-92 For example in the Netherlands, this would 
apply to about 50% of all women screened around age 50,93 
and would translate into a yearly reduction of at least 65,000 
smears, or close to 15% of all programme smears.68, 69 The age 
limit for screening of women with several consecutive negative 
smears continues to spawn interest until today,94 as the discus-
sion could not be closed because of lack of suitable data. Studies 
so far focused on the detection of CIN.18, 90-92, 95-97 Because there 
is strong evidence that CIN has a higher progressive potential 
at older compared to younger ages,34 the comparison of the fre-
quency of detection of these lesions as a proxy for comparing 
the risk for cancer in younger and older women is questionable. 
In Chapter 4, we reassessed the need for continued screening by 
comparing the incidence of cervical cancer. 
4. What is the negative predictive value of the 
HPV test compared to the Pap smear in primary 
screening?
One of the possible applications of an HPV test is to use it as a 
replacement of the Pap smear in primary screening.45 Whether 
this is worthwhile cannot be simply calculated from cross-sec-
tional relative sensitivity and specifi city data. Rather, screening 
programmes would need to be adjusted to achieve the optimal 
gain from the different detection profi le of an HPV test. Depend-
ing on how much more sensitive HPV testing is for the under-
lying cancer precursors compared to the Pap smear,45 and how 
much earlier it detects them,98-100 one of the adjustments would 
be lengthening the screening interval. To investigate this issue, 
women were screened within a multi-centric European project 
with the combination of the Pap smear and the HPV test, and 
thereafter followed for several years. We evaluated the risk for 
CIN 3+ associated with three different combinations of these 
two tests (cytology alone, HPV alone, and a combination of 
both). Our fi ndings on the most optimal procedure, with their 
implications for the future of cervical cancer screening are dis-
cussed in Chapter 5.
5. What is the optimal use of HPV testing in triage of 
women with a persistent low-grade abnormal smear?
Another possible application of HPV testing is in triage of low-
grade cytological abnormalities.101 Women with low-grade cyto-
logical abnormalities in screening smears are in general referred 
to a gynaecologist after one (e.g. in the Netherlands) or more 
abnormal follow-up smears.49, 102, 103 Ten to 40% of these women 
have a CIN 2+ lesion,104-109 and 60-90% do not. About one-half 
have a detectable HPV infection.104-109 In a trial described in 
Chapter 6, we explored the safety of selecting only HPV-positive 
women for a referral to a gynaecologist. In Chapter 7, we addi-
tionally explored the optimal timing of HPV testing in the group 
of women with a persistent low-grade abnormal smear. 
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2.1. Abstract 
The success of screening, an important cancer prevention tool, 
depends on the quality and effi ciency of protocols and guidelines 
for screening and follow-up. However, even centrally organised 
screening programmes such as the Dutch cervical screening pro-
gramme occasionally show problems in performance. To improve 
this programme, the screening scheme, follow-up, administra-
tion and fi nancing protocols and guidelines were thoroughly 
changed in 1996. This study evaluates the consequences for the 
performance of the national programme. The fi ve-year cover-
age rate, the proportion of screened women sent to follow-up, 
follow-up compliance and duration, and the yearly number of 
Pap smears before and after the changes in 1996 were com-
pared. Five-year coverage increased substantially in the added 
target age groups (30-34, and 54-60 years); in the old target 
age group (35-53 years) it remained around 80%. The percent-
age of screened women sent to follow-up decreased from almost 
19% to 3% per screening round, due to a more restrictive use of 
the Pap 2 classifi cation, and an evidence-based cessation of fol-
low-up of negative smears without endocervical cells. Follow-up 
compliance has improved, and the average time until a woman 
is either referred or rejoins the regular screening schedule, has 
become shorter. The total number of smears, a strong determi-
nant of screening costs, has decreased by 20% primarily due 
to the changed follow-up recommendations. In conclusion, the 
1996 changes in protocols and guidelines, and their implemen-
tation have increased the coverage and effi ciency, and decreased 
the screening-induced negative side effects.
2.2. Introduction
Screening is an important cancer prevention tool. In case of 
cervical, colorectal and breast cancer it is recommended110 and 
adopted as national programmes in various countries.111-113 
Depending on the outcomes of ongoing trials,114-116 more 
screening programmes (for prostate, lung and ovary cancer) 
may in the future be offered to the general population. The suc-
cess of screening depends on the quality and implementation of 
protocols and guidelines for primary screening and follow-up. 
Often, the balance between prevented mortality from cancer, 
and the screening-induced costs and negative side effects (e.g., 
higher morbidity, unnecessary treatments and raised anxiety 
due to false-positive results) is fragile.89, 117 Also, people may be 
screened too frequently, while others are not screened at all.118, 
119 Further, new screening tests become available occasion-
ally,120 and these require thorough evaluation before they can 
be incorporated into a screening programme. Screening there-
fore requires regular monitoring and adaptation in order to keep 
the programme effective and effi cient. 
Since the 1980’s, cervical cancer screening with the Pap 
smear has been offered to the population in the Netherlands 
through an organised programme. Pap smear is a non-invasive 
test and aims to prevent cancer deaths by treating pre-invasive 
and early invasive disease. Like in the UK in the 1980’s,121-123 
the evidence gathered in the Netherlands in the early 1990’s 
pointed towards a suboptimally performing programme, in terms 
of both the organisation and the effi ciency of screening of the 
target population.51, 53, 55, 78 In 1993, the Ministry of Health 
called for an immediate inquiry into possible solutions.54 Sub-
sequently, new protocols and guidelines regarding the screen-
ing and follow-up schemes, administration and fi nancing were 
implemented nationally in 1996 (Appendix, Chapter 2.6.).56 The 
new screening and follow-up schemes were agreed upon in a 
consensus meeting of the fi ve professional groups implement-
ing cervical cancer screening (pathologists, gynaecologists, 
general practitioners (GP), regional cancer registries, and local 
health authorities) together with epidemiologists and Ministry 
of Health representatives. Much emphasis was devoted to assur-
ing that the guidelines would be adhered to.124 
Seven main implemented solutions can be distinguished. 
First, since 1996 the programme covers the whole country. 
Financing and coordination are managed centrally. The pro-
gramme is implemented locally through special regional cen-
tres operating in a covenant, i.e. as fi nancially binding asso-
ciations of the fi ve professional groups listed earlier. Second, 
all non-attendees to the fi rst invitation are systematically sent 
reminders. Third, reimbursement of preventive smears taken 
outside of the regular screening schedule, which are considered 
ineffective and may result in unnecessary diagnostic and treat-
ment procedures,78, 125 has been abolished. Fourth, the screen-
ing interval was increased from 3 to 5 years in a broader target 
age group (30-60 instead of 35-53 years).55 Fifth, new pathol-
ogy guidelines49 aimed to improve the specifi city of the Pap 
smear by downgrading the considerable number of smears with 
sole morphocytological signs of infl ammation and/or presence 
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of specifi c microorganisms from a borderline (Pap 2) to a nega-
tive (Pap 1) smear. Sixth, the new pathology guidelines aimed 
to limit the maximum duration of follow-up of borderline (Pap 
2) and mildly (Pap 3a1) dyskaryotic smears (BMD) before the 
fi nal referral or normal screening recommendation. Seventh, an 
amendment from 2002 ceased to advise a repeat Pap smear to 
negative smears lacking endocervical cells (Ecc-).73, 126 
To assess improvement in the Dutch cervical cancer screen-
ing programme after the completion of the fi rst 5-yearly screen-
ing round under the new protocols and guidelines, we will evalu-
ate the impact of these changes on the fi ve-year coverage rate, 
the proportion of screened women sent to follow-up, follow-up 
compliance and duration, and the yearly number of smears. 
2.3. Material and Methods
Performance of the new protocols and guidelines is based on 
programme smears from 2003. The exception is the follow-up 
compliance, which is instead based on programme smears from 
1999 in order to have available data for a 4-year follow-up 
period. This performance of the current programme is compared 
with the situation before 1996, which is based on programme 
smears from 1994.
Information on all cervix uteri cytological and histological 
tests in the Netherlands registered until 31st March 2004 was 
retrieved from the nation-wide network and registry of histo- 
and cytopathology (“PALGA”). From 1990 onwards all pathology 
laboratories were linked to this registry.81 
PALGA identifi es a woman through her birth date and the 
fi rst four letters of the (maiden) name. In order to correct for 
occasional false matches in this identifi cation,127 we excluded 
the 0.5% most common surnames.76 This applies to the results 
in Tables 1, 3, 4 and consequently 6, and excludes about 30% of 
women from the PALGA. Age is defi ned on 1st December of the 
analysed year, in agreement with the defi nition of age at invita-
tion as used in the screening programme. 
For all registered cervical smears, PALGA enables recoding of 
the reason for smear-taking into programme screening, sponta-
neous screening, medical complaints, or follow-up. This infor-
mation is missing for 52% and 10% of the primary smears in 
1994 and 2003, respectively. A programme smear is defi ned as 
any smear in PALGA that was primary and taken in the calendar 
year (or the fi rst three months thereafter) in which the woman 
was eligible for the programme given her birth year. 
Five-year coverage rates are calculated by comparing the num-
ber of women who had at least one smear taken for any reason 
(as counted from PALGA), with the estimated number of women 
at risk (i.e., with a cervix) alive on 1st January of the analysed 
year. The number of women at risk were estimated with the data 
obtained from the Dutch Central Bureau of Statistics,23 decreased 
by the estimated number of women with their cervix removed by 
a hysterectomy.128 Further, we excluded the 0.5% common sur-
names both in the numerator and the denominator. Because the 
latter cannot be obtained from any offi cial statistics, we approxi-
mated the fraction of women remaining in the population at risk 
after the exclusion of 0.5% most common surnames by observing 
the fraction of tests remaining in PALGA after the same exclusion. 
The implicit assumption here is that the screening behaviour and 
the commonness of surnames are not associated.
A screening episode is defi ned as starting with a primary test 
and eventually followed by secondary tests (smears or biopsies). 
Follow-up or secondary tests are tests made within 4 years of 
an abnormal smear, an inadequate quality smear, or a non-neg-
ative biopsy after which follow-up has not yet been completed 
according to the guidelines. All other tests are seen as primary 
tests starting the episode. An episode is fi nished either when 
follow-up is complete according to the current guidelines (e.g., 
two consecutive negative smears after a BMD smear, or three 
consecutive negative smears after treatment of histologically 
confi rmed cervical intraepithelial neoplasia), or when there are 
no more tests registered in 4 years. The categorisation of smear 
results and the corresponding follow-up recommendations are 
presented in the Appendix (Chapter 2.6.). 
Excess smears are defi ned as all smears that are taken in a 
certain period that do not contribute to the observed coverage 
in the target population. These may be due to e.g. more fre-
quent screening than it is recommended, but also due to sec-
ondary (diagnostic) testing. The number of excess smears is pre-
sented for the relevant screening interval and 1,000 women per 
year; it is equivalent to (total yearly number of smears – num-
ber of smears needed yearly to reach the observed coverage) × 
1,000 / number of women in the target group. The number of 
smears needed yearly to reach the observed coverage equals (the 
population at risk in the target age range × observed coverage) 
/ recommended interval. 
2.4. Results
Five-year coverage in the target population reached 77% in 2003 
(Table 2-1), which is 12% points higher than the response to 
screening invitations, i.e. the attendance rate of 65% (data not 
shown). This difference is due to smear-taking outside the pro-
gramme. The coverage in 1994 in the then targeted age group 
(35-53 years) was higher than in the newly targeted age group 
in 2003 (30-60 years). However, given that based on evidence 
it has been decided since 1996 that a larger age group is to 
be reached, the situation has improved. The coverage increased 
substantially in the added target age groups, while in the age 
groups targeted both before and after 1996 it remained at about 
the same level. 
One percent of the programme smears was of inadequate 
quality for evaluation in 2003 (Table 2-2). Moderately dyskary-
otic or worse abnormalities (>BMD) were found in 0.5% of pro-
gramme participants, and further 1.8% of women had a BMD 
smear. The remaining women, 96.7%, had a negative smear. 
Table 2-1. Five-year coverage rates in the Netherlands 
before (1994) and after (2003) the implementation of the 
new cervical cancer screening protocols and guidelines, for 
women aged 30-64, per age group. 
Age group 2003 1994
30-34 68% (53%)
35-39 77% 81%
40-44 81% 83%
45-49 81% 82%
50-54 81% 82%
55-59 79% (59%)
60-64 74% (23%)
Total 77% 82%†
()=Became part of the target age groups from 1996 onwards. 
†Based on ages 35-54.
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Compared with the situation in 1994, there are two interest-
ing differences. First, there was a more than 80% decrease in 
the frequency of a follow-up smear advice. This was caused by 
the change in the defi nitions regarding the classifi cation of sole 
morphological signs of infl ammation. Second, immediate refer-
ral recommendation because of high-grade cytological abnor-
malities has almost doubled in frequency because since 1996 
moderately dyskaryotic smears (Pap 3a2) also fall into this cat-
egory (Appendix, Chapter 2.6.). 
Among women with a 6-month follow-up smear advice (BMD 
smears), 74% received follow-up within 9 months, which we 
defi ne as timely follow-up according to the guidelines (Table 
2-3). Compared with 1994, the compliance with follow-up 
guidelines has increased substantially. There has also been an 
increase in longer-term follow-up (measured within four years). 
The time in follow-up for these women until the fi nal referral 
or a screening recommendation was shorter than in 1994 (Table 
2-4). This difference is especially notable for women with a neg-
ative follow-up outcome: they were on average recommended to 
rejoin the normal screening schedule 12 months earlier than in 
1994. Women with a positive follow-up outcome were on aver-
age referred to a gynaecologist 4 months earlier. Moreover, after 
on average 4.6 years, fewer women had no clear fi nal follow-up 
recommendation in 1999 than in 1994. The average number of 
tests performed before the fi nal either referral or a screening 
recommendation decreased by 10% (data not shown). 
In the recent period, 85% of the women with a direct refer-
ral advice (>BMD smears) received follow-up in time (3 months), 
which increased to 97% within 4 years (Table 2-3). This compli-
ance has not improved since 1994, but did also not worsen even 
though the new protocols on immediate referral include the 
moderately dyskaryotic smears (Pap 3a2). Among the 97% of fol-
lowed-up women, 94% had at least one biopsy. For smears that 
need to be repeated due to inadequate quality the follow-up 
compliance has remained similar. However, contrary to recom-
mendations these women were in 1994 more often referred and 
biopsied immediately instead of having a repeat smear taken. 
In 2003, programme smears represented 67% of all smears, 
and those taken for medical complaints 13%. Spontaneous 
screening was small in volume at less than 2% of the total screen-
ing activity. Together with those smears for which no reason for 
smear-taking is given, primary smears add up to 91% of all smears 
(Table 2-5). Secondary smears account for 9% of all smears.  
In total, 787,506 smears were taken in 2003, which repre-
sents an overall drop of 20% since 1994 (Table 2-5). Compared 
with 1994 and adjusted for population growth, the number of 
primary smears was about 2% lower in 2003. The decreased num-
ber of primary smears coupled with an increased coverage in a 
broad age range must have been associated with a longer aver-
age interval between consecutive primary smears. Indeed, both 
the frequency of very short screening intervals, as 
well as of the intervals of 2-4 years decreased (data 
not shown). The effect of the screening scheme 
protocol change is here intertwined with better 
adherence to these protocols. Moreover, there was 
less screening outside of the target ages, especially 
among women before their thirties (Table 2-6). Sec-
ondary smears dropped by 73% between 1994 and 
2003 (Table 2-5). This drop was in approximately 
two-thirds due to how smears are evaluated with 
regard to infl ammation (i.e., the Pap 2 defi nition 
change), and in the remaining third due to ces-
sation of follow-up to Ecc- smears since January 
2002. 
2.5. Discussion
Since the 1996 changes the performance of the 
Dutch cervical cancer screening programme has 
improved considerably. With the same number of 
7 smears per lifetime in a broader age range, the 
5-year coverage in the added target age groups 
(30-34, and 54-60 years) rose substantially to 70% 
or above, with a loss of a few percent in the old 
target age group (35-53 years) where the cover-
age remained around 80%. This better coverage 
Table 2-2. Primary smear results in the organised cervical 
cancer screening programme before (1994) and after 
(2003) the implementation of the new protocols and 
guidelines, by type of follow-up recommendation.
Follow-up 
recommendation
2003 1994
No follow-up
Due to a negative smear 84.8% 81.1%
Due to an Ecc- smear† 11.9% 7.3%
Follow-up
Follow-up smear 1.8% 10.0%
Immediate referral 0.5% 0.3%
Repeat smear due to 
inadequate quality
1.0% 1.3%
Total 100% 100%
†Before 2002, the guidelines recommended Ecc- smears 
to be repeated after one year. Since January 2002, this 
recommendation has been withdrawn.
Table 2-3. Compliance with follow-up after primary screening 
programme smears before (1994) and after (1999) the implementation 
of the new protocols and guidelines, by type of follow-up 
recommendation. 
Follow-up recommendation 1999 1994
Follow-up smear 
Percentage of programme smears 2.1% 10.0%
– Of which with timely follow-up† 74%‡ 44%‡
– Of which followed-up in 4 years* 90% 78%
– Of which with a biopsy (of *) 27% 14%
Immediate referral 
Percentage of programme smears 0.6% 0.3%
– Of which with timely follow-up† 85% 91%
– Of which followed-up in 4 years* 97% 97%
– Of which with a biopsy (of *) 94% 95%
Repeat smear due to inadequate quality
Percentage of programme smears 0.8% 1.3%
– Of which with timely follow-up† 42% 45%
– Of which followed-up in 4 years* 85% 85%
– Of which with a biopsy (of *) 3% 18%
†Defi ned as 150% of the recommended follow-up interval, or 3 months for 
immediate referral. ‡First step of follow-up only.
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was achieved with a 20% lower number of smears. The share of 
women sent to anxiety-causing follow-up decreased from 19% 
to 3% per screening round. Ninety percent of these women, an 
increase of 11% points, were followed-up after their non-neg-
ative screening smear. They spent a considerably shorter time 
in follow-up before they were either referred, or rejoined the 
regular screening schedule (Table 2-6). These results contrib-
ute towards gains in effectiveness and effi ciency, and a reduc-
tion in screening-induced negative side effects and costs associ-
ated with cervical cancer screening in the Netherlands. Because 
before 1996 for slightly more than a half of the primary smears 
the reason for smear-taking was not known, in an additional 
analysis we included these smears. The pooled estimate of smear 
non-negativity rate in 1994 was 16% instead of 19% reported in 
Table 2-2, and the recent 3% still represents an 81% reduction 
since 1996 (instead of 84% reduction compared to 19%). 
Coverage is a major effectiveness determinant of cervical 
cancer screening.129, 130 In the age groups targeted both before 
and after 1996 (35-53 years) a small decrease in 5-year cover-
age rates was observed (Table 2-1). It appears that the lower 
frequency of invitations (one invitation every fi ve instead of 
three years) has been counteracted by the benefi cial effects of 
the 100% (i.e., nation-wide) invitation coverage and system-
atic reminders. Recent evidence131 has shown that the uptake 
of screening is higher when the invitation is sent by the GP as 
opposed to the municipality. Further expansion of a GP invi-
tational system is currently under review. The English experi-
ence with introducing graded fi nancial incentives for the GPs to 
stimulate coverage has been positive,103 though feasibility and 
acceptability of implementing such an instrument in the Dutch 
health care is not known. 
Sending fewer women to follow-up, i.e. an increase in 
test specifi city, has the potential of decreasing test sensitiv-
ity. Because of the low predictive value for (future) cancer 
of borderline dyskaryotic smears,132, 133 and the long average 
screen-detectable preinvasive period for cervical cancer,32-34 it 
is expected that when women are regularly screened, less inten-
sive follow-up will only lead to a very small loss in program sen-
sitivity. The CIN 3+ detection rates, i.e. the number of histologi-
cally confi rmed cervical intraepithelial lesions grade 3 or higher 
per 1,000 women screened, increased 
from 4.4 to 5.4 (i.e., by 22%) between 
1994 and 1999 (corrected for the 
extent of default to follow-up; data 
not shown). If anything, this does not 
point at lower sensitivity. However, 
even assuming no change in sensitiv-
ity, this increase was expected due to 
both an earlier start of programme 
screening (higher incidence and prev-
alence of CIN in young women), and 
a longer screening interval in 1999 
than in 1994 (higher within-interval 
cumulative incidence of CIN 3). It is 
unknown to what extent changes in 
the detection rates are due to changes 
in the degree of over-diagnosis. A bet-
ter indicator of the potential change 
in programme sensitivity, i.e. the 
interval cancer rate, is going to be 
examined in later analyses. 
There is quite a diversity in how cervical cancer screen-
ing is organised in Europe,111, 134 and its performance varies 
widely.70 Compared to other countries with organized national 
programmes (Table 2-7), the Netherlands has been successful 
in limiting the number of excess smears while maintaining a 
high coverage rate. For example, even though the recommended 
screening interval is 5 years in Finland, the yearly number of 
smears is enough to screen each woman in the target age every 
2.1 years, compared to every 4.7 years in the Netherlands. There 
are several reasons for this phenomenon. Contrary to Finland, 
procedures exist in the Netherlands (likewise in Sweden and 
England) that help sort out women with very recent smears. 
Next, smears taken outside of the regular screening schedule are 
in the Netherlands only reimbursed when the woman has medi-
cal complaints. Finally, Pap-smear screening in the Netherlands 
primarily takes place in GP practices, and much attention has 
been paid in the Dutch guidelines for GP practices to the fre-
quency of smear-taking.57 
The structure of follow-up advices given in the programme 
also differs among countries. While the Netherlands and Finland 
both have a low rate of inadequate smears, the sample inade-
quacy rate in England is close to 10%. This is one of the reasons 
why liquid-based cytology is considered a cost-effective option 
in England141 and not in the Netherlands.142 England and Fin-
land have a high positivity rate of around 7%. The Netherlands 
and Sweden are both low with 2.3% and 1.5%, respectively. The 
fact that the bulk of the differences disappears if one compares 
the frequency of only highly positive programme smears is con-
sistent with the view that the countries are using widely dif-
fering defi nitions of BMD abnormality. Therefore, the planned 
comparison of interval cancer rates before76 and after the sharp 
decline in the proportion of BMD smears in the Netherlands will 
also be interesting from an international perspective. 
The observed improvement in the Dutch cervical cancer 
screening programme was achieved in a short time. Implemen-
tation of protocols and guidelines is a complex process that 
depends on both the protocols and the guidelines themselves 
as well as on the context in which they are implemented.143, 
144 In the Netherlands, the new protocols and guidelines49, 57, 59 
Table 2-4. Final recommendation for women with a 6-month follow-up smear 
advice (to rejoin the normal screening schedule, or a referral to gynaecologist), and 
average duration until fi nal recommendation, before (1994) and after (1999) the 
implementation of the new protocols and guidelines.
Frequency Average time (months)∫
1999 1994 1999 1994
Referred 31% 7% 10 14
Sent back to screening 32% 24% 25 37
Early histology† 4% 7% 5 12
Undetermined follow-up‡ 24% 46% n.a. n.a.
Without any follow-up 9% 16% n.a. n.a.
Total 100% 100%
Based on average follow-up time of 4.6 years per woman (range: 4.0 to 5.3 years). 
n.a.=not applicable. †Women with a histological result registered before it is expected 
according to the follow-up guidelines. ‡Women with follow-up, yet without test results 
suggesting a referral or a screening recommendation, and without early histology. 
∫Time between the programme smear and the test that determined the fi nal follow-up 
recommendation conforming to the guidelines. 
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(Appendix, Chapter 2.6.) were developed by recognized organi-
sations of those professionals who perform smear-taking and 
pathology evaluation, and were based on available evidence. In 
many instances, such as for follow-up, they simplifi ed and made 
clearer the recommended algorithms of care. In turn, adherence 
to the new protocols and guidelines was stimulated with those 
instruments that have proved to be effective in prevention, e.g. 
educational outreach visits and specialised software modules.124, 
Table 2-5. Numbers of primary and secondary smears (× 1,000), by screening age group, before (1994, adjusted for 
population growth between 1994 and 2003) and after (2003) the implementation of the new protocols and guidelines. 
Primary smears Secondary smears Total
Age group 2003 1994 2003 1994 2003 1994
<30 28 106 4 26 32 (4%) 132 (13%)
30-60 666 598 61 214 727 (92%) 812 (83%)
>60 26 29 3 9 29 (4%) 37 (4%)
Total 720 (91%) 733 (75%) 68 (9%) 248 (25%) 788 (100%) 981 (100%)
Table 2-6. Summary: effectiveness, screening-induced side effects, and effi ciency indicators before and after the 
implementation of the new protocols and guidelines in 1996.
Process indicator After 1996 Before 1996
Effectiveness
Coverage in the target age group† 77% 82%
Overall compliance to follow-up‡ 90% 79%
Screening-induced negative side effects
Proportion of women with a follow-up advice 3% 19%
Average time in follow-up before sent back to screening 
(women with a follow-up smear advice) 25 months 37 months
Effi ciency
Number of excess smears per year per 1,000 women in the target age group∫ 76 261
Number of smears per 1,000 women aged 20-29, per year 33 111
†After 1996: 30-64 years, before 1996: 35-54 years. Coverage in the overlapping target age range (35-54 years): 80% after 1996, 
82% before 1996. ‡Weighted average of compliance with follow-up in 4 years from Table 2-3. ∫Calculated as (total yearly number 
of smears – number of smears needed yearly to reach the observed coverage) × 1,000 / number of women in the target group. The 
number of smears needed yearly to reach the observed coverage equals (the population at risk in the target age range × observed 
coverage) / recommended interval.
Table 2-7. Comparison of the current Dutch cervical cancer screening programme with other cervical cancer screening 
programmes in terms of process indicators.70, 135-140 
The Netherlands Finland England (UK) Sweden
Cervical cancer mortality per 100,000† 1.9 0.9 2.1 1.7
Organised programme characteristics
Target age group 30-60 30-60 25-64 20-60
Screening interval (years) 5 5 3-5 2-4
Number of recommended smears per lifetime 7 7 12 14
Organised programme performance
Share of smears within the programme‡ 67% 37% 75% 39%
Target population / total number of smears 4.7 2.1 3.5 2.5
5-year coverage in the target group 77% 93% 81% <82%∫
% Inadequate quality 1.0% 0.01% 9.3% n.a.
% Positive smears§ 2.3% 7.3% 6.4% 1.5%
- Of which highly positive∞ 0.5% 0.6% 1.1% n.a.
n.a.=not available. †Age-standardised rates, for the last available year: The Netherlands 2000, England and Finland 2002, Sweden 
2001. ‡The Netherlands: primary programme smears compared with total number of smears; Finland: programme smears compared 
with spontaneous smears; England and Sweden: programme smears compared with the total number of smears. ∫3-yearly coverage. 
§Positive smears: the Netherlands, Finland: ≥Pap 2; England: ≥borderline dyskaryosis; Sweden: ≥CIN 1. ∞Highly positive smears: the 
Netherlands: Pap3a2+; Finland: Pap3+; England: ≥moderate dyskaryosis.
Population data sources: The Netherlands: Central Bureau of Statistics;23 Finland: Statfi n; England: Department of Health;137 
Sweden: Swedish National Board of Health and Welfare.
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145 Responsibility for implementing the programme according to 
the agreed protocols, which was also secured with fi nancial stip-
ulations, was put in the hands of the regional screening centres 
that are backed by the covenant of the fi ve professional groups 
with an interest in cervical cancer prevention. Early encouraging 
evidence from the new programme62 could have further helped 
stimulate adherence to the pace set out in the protocols. 
In conclusion, the 1996 evidence-based change of proto-
cols and guidelines regarding the screening scheme, follow-up, 
administration and fi nancing has brought about a considerable 
improvement in the cervical cancer screening programme in the 
Netherlands. It was made possible by continuous evaluation 
based on national pathology registry data, timely dissemination 
of results, and carefully developed change and implementation 
phases. 
Acknowledgments
This study was fi nanced by the National Health Insurance Council 
(College voor Zorgverzekeringen, grant number 530/003/2002). 
Authors wish to thank Statfi n and the Swedish National Board 
of Health and Welfare for providing the population data for Fin-
land and Sweden, respectively. 
2.6. Appendix: Overview of the changes in 
the cervical cancer screening protocols and 
guidelines in the Netherlands in 1996.
Table 2-A1. Protocols and guidelines regarding screening, fi nancing and administration in the cervical cancer screening 
programme in the Netherlands, before and after 1996.
Before 1996 After 1996
Screening scheme
Target age range 35-53 years, but in practice it varied from 
25-55
Uniformly 30-60 years
Screening interval 3 years 5 years
# Smears per lifetime 7 7
Invitation Personal letter of the local health authority 
or the chosen GP, or through mass media
Personal letter of the local health authority 
or the chosen GP
Reminder Not systematic Mandatory
Follow-up See Table 2-A2 See Table 2-A2
Financing
Financing of the implementation of 
the programme
Non-earmarked municipal funds for health 
care in general
Earmarked funds managed centrally 
Programme smear reimbursement 
(GPs and pathologists)
Health insurance, out-of-pocket payments, 
non-earmarked municipal funds
Non-programme smear 
reimbursement 
Reimbursed by health insurance, out-of-
pocket payments
Not reimbursed and discouraged in guidelines 
for GPs (unless with medical complaints)
Administration
Geographical coverage 85% of the municipalities (estimated) National coverage
Coordination Local, varies by region/municipality (local 
cancer registries, health authorities, 
municipalities, special work groups, none)
National (National Health Insurance Council. 
From 2006: National Institute for Public 
Health and the Environment)
Implementation Local, varies by region/municipality 
(municipalities, local health authorities)
Local (screening centres), always under a 
covenant of the fi ve local parties: health 
authority, cancer registry, GPs, pathologists, 
and gynaecologists
Programme evaluation Not systematic Integrated into the programme (with a special 
budget)
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3.1. Abstract
The defi nition of minimal relevant Pap smear abnormality is cru-
cial for balancing the benefi cial effects of screening (prevented 
mortality) with negative side-effects (the high positivity rate). 
After infl ammation ceased to be defi ned as a borderline abnor-
mal smear outcome in the Netherlands in 1996, the proportion 
of these smears dropped from 10% to less than 2%. Because 
this may have caused a loss in smear sensitivity, we analysed 
the changes in the incidence of cervical cancer after a negative 
Pap smear. All negative smears made at ages 30-64 in 1990-
1995 (n=1,546,252) and 1998-2006 (n=3,552,716), registered in 
the national registry of histo- and cytopathology (PALGA), were 
followed for up to 9 years. During follow-up of the 1990-1995 
smears, 377 women developed cervical cancer within 5,232,959 
woman-years at risk, while during the follow-up of the 1998-
2006 smears, 619 women developed cervical cancer within 
11,210,675 woman-years at risk. The cumulative incidence after 
the defi nition change was not signifi cantly higher than before: 
e.g. at 6 years, the cumulative incidence for smears made in 
1990-1995 was 46 per 100,000 (95% CI: 41-52), and for smears 
in 1998-2006 was 48 per 100,000 (95% CI: 43-54), P=0.59. The 
hazard ratio for 1998-2006 compared to 1990-1995 adjusted for 
age, number of previous negative smears and history of abnor-
malities was 0.90 (95% CI: 0.78-1.03). In the Netherlands, a 
setting with high-quality cytological screening, treating smears 
with only signs of infl ammation as negative leads to a consider-
ably lower positivity rate without increasing the risk for cervical 
cancer after a negative smear.
3.2. Introduction
The number of women who benefi t from cervical cancer screening 
(estimated at about 1%)1, 146 is small compared to the number 
that bear a considerable burden of non-negative screening out-
comes (2-10% per screening round).147-151, Chapter 2 Women with 
non-negative cytologic fi ndings are advised to stay in follow-
up, and sometimes need to undergo colposcopy and treatment 
for preinvasive lesions which most often would not have devel-
oped into cancer.32, 37 It is therefore crucial to set an appropriate 
threshold for the minimal level of relevant smear abnormality. 
In the Netherlands, the current defi nition of this threshold, 
i.e. of borderline dyskaryosis (ASCUS), was agreed upon in 1996 
as part of the major changes in the cervical cancer screening 
programme.152, Chapter 2 Since 1996, infl ammatory changes with-
out dysplasia are seen as benign for cervical neoplasia and are 
included in the category of a negative rather than a borderline 
dyskaryotic Pap smear.49 This guideline defi nition is comparable 
to that in many other countries, e.g. England and the USA.40, 
50, 153 
This change had a tremendous impact on the Dutch screen-
ing practice. During the 1980’s and the early 1990’s, about 10% 
of smears were judged borderline dyskaryotic (including infl am-
mation).51, 86 It was recommended to follow up this group of 
women with yearly smears until they had two consecutive nega-
tive smears and could thereafter rejoin the regular screening 
programme, or until their cytologic diagnosis worsened and they 
were referred to colposcopy.154 In practice, it took several years 
before such a decision could be made.Chapter 2 After the guide-
lines began to recommend classifying infl ammation as a nega-
tive screening outcome, the proportion of borderline dyskaryotic 
smears decreased to less than 2% (1.5% for programme smears), 
whereas the remaining 80% of pre-1996 borderline smears are 
now classifi ed as negative.93 
Broadening the defi nition of a negative Pap smear with 
infl ammation could cause a loss in smear sensitivity, though 
this has never been adequately studied. The Dutch observational 
experiment combined with the existence of nationwide compre-
hensive registration of total screening activity linked to diag-
nostic histological outcomes (including cancer) at the individual 
level since 1990 give a unique opportunity to study whether 
this has been the case. We analysed the changes in the inci-
dence of invasive cancer after a negative smear (i.e., interval 
cancers) before and after the defi nition change. 
3.3. Material and Methods
Information on all cervix uteri cytological and histological tests 
in the Netherlands registered until 31st March 2007 was retrieved 
from the nation-wide network and registry of histo- and cytopa-
thology (“PALGA”).93 The registration began in the late 1970’s, 
and achieved practically complete coverage of pathology reg-
istries in 1990.81 PALGA identifi es a woman through her birth 
date and the fi rst four letters of the maiden name. This identifi -
cation string enables the linkage of different tests belonging to 
CHAPTER 3. No Increased Risk for Cervical 
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the same woman, and therefore also to follow individual testing 
histories (dates and diagnoses). The problem of false identity 
matches127 was avoided by excluding women with 0.5% most 
common maiden names which corresponds to approximately 
30% of all women.76 
Registered screening histories were organized into screen-
ing episodes. An episode is defi ned as starting with a primary 
test (a smear or a biopsy) followed by secondary tests in case 
this test was abnormal (at least borderline dyskaryosis) or of 
inadequate quality. Follow-up or secondary tests were defi ned 
as the tests made within 4 years following the primary test, 
unless the follow-up of this primary smear had already been 
completed according to the guidelines49, 59 (e.g., with two con-
secutive negative smears after a borderline dyskaryotic smear, 
or three consecutive negative smears after histologically con-
fi rmed cervical intraepithelial neoplasia (CIN)). All other tests 
were seen as primary tests. 
We identifi ed women with cervical cancer by selecting all 
PALGA records that included pathology codes for cervical can-
cer between 1994 and 2006. For these women, we reviewed the 
free text of all histology reports in PALGA. Complete follow-up 
(woman-years at risk and cases) was therefore left-censored at 
the beginning of 1994 and right-censored at the end of 2006. 
Cases and woman-years at risk were counted for at most 9 years 
from a negative primary smear until the primary smear of the 
next episode (or the date of the fi rst histologically proven diag-
nosis of cervical cancer if it was diagnosed in the next epi-
sode (cases)), or else until 31st December 2006. Because dur-
ing the analysed period the reason for smear-taking was not 
always registered in PALGA, all cancers originating in the cervix 
were counted as cases regardless of the reason for the primary 
investigation. Thus, all invasive cervical cancers diagnosed sub-
sequent to a negative primary smear, including screen-detected, 
were counted as cases.
We compared negative primary smears taken in calendar 
periods 1990-1995 and 1998-2006. Smears made in 1996-1997 
were excluded from the analysis because this was a transi-
tion period in which the proportion of borderline smears was 
still high but decreasing (1996: 5.5%, 1997: 3.3%).93 First, the 
cumulative incidence rate (CIR) of interval cancer was calcu-
lated for each period for women aged 30-64 at the time of the 
primary smear. We focused on the 6-year CIR because this period 
covers the next screening round scheduled to take place 5 years 
after a negative smear. The 95% confi dence intervals were esti-
mated by non-parametric Kaplan-Meier product-limit estimator 
for log(hazard).155 Second, the relative hazards were estimated 
by univariate and multivariate Cox regression with left and right 
censoring. In the univariate model, period (1998-2006 vs. 1990-
1995) was entered as the explanatory variable; in the multivari-
ate model also age at primary smear (grouped as 30-34, 35-39, 
40-44, 45-49, 50-54, 55-59, 60-64 years), the number of previ-
ous negative primary smears (1st negative smear vs. 2nd or later 
consecutive negative smear), and the history of abnormalities 
(no cytologic or histologic abnormality vs. at least a border-
line negative smear in the past) were entered. Time dependency 
of the relative hazards was statistically tested by splitting the 
total follow-up time in two periods with a roughly equal number 
of cases. This leads to two new datasets where the full model is 
fi tted on again. If the sum of the deviance of both sub-models 
is signifi cantly lower than the deviance of the original model, 
the parameter estimates differ signifi cantly between the two 
periods. 
The detection rates of CIN grades 1, 2 and 3, and invasive 
cancer, i.e. the proportion of primary smears with a histolog-
ically confi rmed cervical lesion, were calculated as the num-
ber of these lesions (numerator) per 1,000 smears in previ-
ously unscreened women aged 30-64 (denominator). To allow 
for follow-up, the most severe histologically confi rmed diagno-
sis within 27 months of an abnormal smear was used as the 
fi nal diagnosis. The age-adjusted odds ratios for periods Janu-
ary 1998-September 2004 vs. January 1994-December 1995 were 
estimated with logistic regression. 
3.4. Results
We identifi ed 1,546,252 negative smears made in 1990-1995 
that contributed woman-years in the analysis, and 3,552,716 
negative smears in 1998-2006 (Table 3-1). These were made 
in 1,136,631 and 2,005,627 women, respectively (2,314,250 
women in total). The age at which these smears were taken 
was somewhat higher in the 1998-2006 period. The negative 
smears from the 1990-1995 period were more likely 1st rather 
than 2nd or later consecutive negative smears, and had there-
fore fewer previous abnormalities than those from the 1998-
2006 period. 377 women were diagnosed with an invasive can-
cer in 5,232,959 woman-years at risk following a negative smear 
made in the 1990-1995 period, and 619 women in 11,210,675 
woman-years at risk following a negative smear made in the 
1998-2006 period. 
Table 3-1. The characteristics of negative primary smears, 
by period: 1990-1995 (1,136,631 women) and 1998-2006 
(2,005,627 women). 
1990-1995 1998-2006
Number of negative primary 
smears
1,546,252 3,552,716
Age at negative primary 
smear:
30-39 years 42% 36%
40-49 years 39% 34%
50-59 years 17% 25%
60-64 years 2% 5%
Length of follow-up:
Less than 2 years 16% 34%
2-4 years 42% 28%
4-6 years 20% 31%
6 years or more 23% 7%
Smear history:
1st negative smear 40% 21%
2nd or later negative smear 60% 79%
Previous abnormalities:
No previous abnormality 82% 74%
Previous at least cytological 
borderline dyskaryosis
18% 26%
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The cumulative incidence rate (CIR) for the 1998-2006 neg-
ative smears was never signifi cantly higher than that for the 
1990-1995 smears (Figure 3-1). At 6 years, the CIR were 46 (95% 
CI: 41-52) and 48 (43-54) per 100,000 negative smears in the 
1990-1995 and the 1998-2006 periods, respectively (P=0.59). 
The univariate hazard ratio was 0.88 (0.77-1.00) for 1998-2006 
vs. 1990-1995. The multivariate hazard ratio adjusted for age at 
the primary smear, the number of previous consecutive negative 
smears, and the history of abnormalities was 0.90 (0.78-1.03) 
and therefore not substantially different from the univariate 
hazard. The test for time dependency of the relative hazards was 
statistically non-signifi cant (P=0.45).
The detection rate of CIN 1 in previously unscreened women 
showed a 38% statistically signifi cant decrease after 1998, 
whereas the detection rate of CIN 2+ increased by 22% (Table 
3-2). The positive predictive value (PPV) of an abnormal primary 
smear (borderline dyskaryosis or worse) for CIN 2+ more than 
tripled in the recent period. 
3.5. Discussion
In the Netherlands, treating infl ammatory smears as a nega-
tive screening outcome decreased the proportion of borderline 
smears by 80%.86 In spite of this, 
no increase in the risk for cervi-
cal cancer among women with a 
negative smear could be observed 
(Figure 3-1). This conclusion was 
based on a large observed series 
of cases that produced relatively 
narrow confi dence intervals.
An increased cancer risk asso-
ciated with infl ammation could 
have been diluted in this com-
parison because it represents a 
small proportion (less than 10%) 
of all negative smears. In order 
to gain a more detailed insight 
into the risk associated specifi -
cally with infl ammation, we addi-
tionally compared the detection 
rates of CIN and cancer before 
and after the change in the defi -
nition. We limited the analysis of 
the detection rates to previously 
unscreened women in order to 
obtain an unbiased comparison 
regarding their screening his-
tory. An unchanged detection 
rate would imply that there is no increased risk associated with 
infl ammation, whereas a decrease would suggest an increased 
risk. The observed overall detection rates for CIN 2+, however, 
show that the programme’s ability to detect cervical lesions was 
not diminished after 1996 (Table 3-2). Limiting these detection 
rates to the CIN lesions found after a borderline dyskaryotic 
smear also showed an increase (data not shown). The observed 
increase in the detection rates must be due to other factors. 
Indeed, since 1996 borderline smears had a more complete fol-
low-up, and biopsies were taken more often than before 1996.
Chapter 2 On its own, the latter suggests that the narrower defi -
nition of a borderline dyskaryotic smear has been perceived as 
a more serious screening outcome, and tended to improve the 
quality of follow-up. 
Since screen-detected cancers were included in the analy-
sis, we evaluated whether our results were affected by a change 
(i.e., a decrease) in the screening frequency between the peri-
ods.152 At 6 years, the 1998-2006 cumulative “incidence” of a 
subsequent smear after a negative smear was 9% lower than 
after a smear made in 1990-1995.93 The effect of this small dif-
ference was further reduced because only part of the cancers 
(estimated <50%)93 are screen-detected. 
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Figure 3-1. Incidence of cervical cancer: Cumulative incidence rate of invasive cancer 
per 100,000 negative primary smears at age 30-64, by calendar period in which the 
negative smear was taken.
Table 3-2. Detection rates of CIN and invasive cancer per 1,000 primary smears in previously unscreened women aged 30-
64, by calendar period, and age-adjusted odds ratios (95% CI).
All primary smears Abnormal primary smears†
1994-1995 1998-2004 OR 1994-1995 1998-2004 OR
Number of smears 150,704 387,331 18,665 16,594
CIN 1 4.8 3.0 0.7 (0.6-0.8) 31 62 2.0 (1.8-2.2)
CIN 2 2.9 3.4 1.1 (0.9-1.2) 21 73 3.1 (2.7-3.5)
CIN 3 7.8 9.9 1.2 (1.1-1.2) 60 222 3.9 (3.6-4.1)
Cervical cancer 1.2 1.2 1.1 (0.9-1.3) 9 26 3.4 (2.8-4.0)
†Borderline dyskaryosis or worse.
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All smears and histologically diagnosed CIN and cervical 
cancers are in principle registered in PALGA. In the Netherlands, 
this is the only comprehensive registry that links the cancer 
cases with their screening history. In PALGA, the total number 
of women aged 30-74 with an incident cervical cancer in the 
period 1994-2003 was 10% higher than published by the Cancer 
Registry.4 There was no trend in the differences between the two 
sources by calendar year. Thus, while the interval cancer rates 
may have been somewhat overestimated, the comparison of the 
periods was not biased. 
Even though the recommended defi nition of borderline 
dyskaryosis is similar in several countries, the observed smear 
abnormality rates vary substantially. The diagnosis of borderline 
dyskaryosis is made in 1.5% of the programme smears between 
ages 30 and 64 in the Netherlands, 3% in England and almost 
5% in the USA.93, 156, 157 This variation could be due to genu-
ine differences in the background risk, or to the differences in 
smear interpretation. The differences in the observed incidence 
rates are small,1 while the country-specifi c screening intensi-
ties are similar.118, 150, Chapter 2 This suggests that the background 
risk is comparable. On the other hand, systematic differences in 
the interpretation of borderline dyskaryosis have been shown to 
exist, with the tendency in England and the USA to classify sub-
tler lesions as borderline abnormal.158 This suggests that there 
may still be room for decreasing the smear abnormality rates in 
these other countries.
This observational experiment with broadening the defi -
nition of a negative smear took place in a setting with high-
quality cytology practice. In the Netherlands, strict qual-
ity assurance measures aimed at improving and standardising 
smear interpretation are set out in professional guidelines.49, 
58 Nation-wide pro-forma reporting for cytology was introduced 
in 1996, and instruction CD-ROMs with guidelines and visual 
analogues were distributed to every cytotechnician.49, 159 Labo-
ratory-specifi c feedback is provided to all pathology laboratories 
in the framework of continuous monitoring. 
The balance between the positivity rate (i.e., the proportion 
of smears with a positive outcome) and increased cancer pre-
vention is also relevant in HPV screening. The positivity rates 
of the most widely used HPV tests are 2 to 4 times higher than 
those of conventional cytology.98, 99 Partly, the higher abnor-
mality rate will represent a loss in specifi city, but unlike with 
infl ammation, a gain in sensitivity can be expected.98, 99 These 
will have to be weighted against each other after pooling the 
data on interval cancers from the currently on-going HPV tri-
als,160 which will allow an even more accurate estimate of the 
true increase in the sensitivity. 
In conclusion, excluding infl ammatory changes from the 
defi nition of borderline dyskaryosis in the Netherlands led to an 
80% decrease in borderline abnormal smears without increasing 
the risk for cervical cancer after a negative smear. 
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4.1. Abstract
Objectives. After several consecutive negative Pap smears by 
age 50, the detection rates of preinvasive cervical lesions (CIN) 
are considerably lower than among similarly screened younger 
women. Several authors concluded that continued screening in 
these older women might be ineffi cient. Because CIN is only a 
surrogate outcome measure, and its regression rates are age-
dependent, we compared the incidence of cervical cancer after 
several negative smears at different ages. Design. Prospective 
observational study of cervical cancer incidence after the third 
consecutive negative smear based on the individual-level data 
in a national registry of histo- and cytopathology (PALGA). 
Setting. The Netherlands, national data. Population. 218,847 
women aged 45-54, and 445,382 aged 30-44 years at the time of 
the third negative smear. Main outcome measures. The 10-year 
cumulative incidence of interval cervical cancer (CIR). Results. 
105 women developed cervical cancer within 2,595,964 woman-
years at risk after the third negative smear at age 30-44, and 42 
within 1,278,532 woman-years at risk after age 45-54. During 
follow-up, both age groups had similar levels of screening. After 
10 years of follow-up, the CIR of cervical cancer was similar: 41 
per 100,000 (95% CI: 33-51) in the younger, and 36 per 100,000 
(24-52) in the older group (P=0.48). The CIR of CIN 1+ was twice 
as high in the younger compared to the older group (P<0.001). 
Conclusions. The risk for cervical cancer after several negative 
smears by age 50 is similar to that at younger ages. It would 
thus not be consistent to stop screening women with several 
consecutive negative smears after age 50, while not relaxing the 
screening policy at younger age.
4.2. Introduction
The debate on earlier cessation of cervical cancer screening for 
women with several consecutive negative smears by age 50 has 
been on-going for about 15 years without drawing clear conclu-
sions in terms of guideline recommendations. Several authors 
studied this issue by analysing the detection rates of prein-
vasive cervical lesions (CIN) in these women.18, 90-92, 95-97, 161, 
162 In general, they observed considerably lower detection rates 
than in similarly screened younger women. Based on this fi nd-
ing, they argued that continued screening is not as effi cient as 
among younger women, and could be stopped at the expense 
of only a limited increase in the incidence of cervical cancer 
among these older women.90, 92, 95, 97 If true, this could result in 
considerable savings for the screening programmes. For example, 
in the Netherlands it would apply to about half of the women 
attending screening around age 50.93 
However, because there is strong evidence that CIN lesions 
have a higher probability to progress to invasive cancer at older 
ages,34 lower detection rate of CIN after age 50 alone do not rep-
resent conclusive evidence for lower screening effi ciency. This is 
refl ected in the fact that the guidelines have not been adjusted. 
Data on invasive cancer has since become available in a Dutch 
nationwide pathology registry with screening histories linked to 
diagnostic histological outcomes (including cancer) at the indi-
vidual level. The aim of this paper was to measure the incidence 
of invasive cancer after several consecutive negative smears in 
women around age 50, and in younger women. This will bypass 
the problems associated with using CIN lesions, and enable a 
more conclusive evaluation of whether there is more reason to 
relax screening in older than in younger women with similar 
negative screening histories. 
4.3. Methods
Data
From the Dutch nationwide network and registry of histo- and 
cytopathology (PALGA), we retrieved information on all cervix 
uteri cytological and histological tests until 31st March 2004. 
The registration began in the late 1970’s, and achieved practi-
cally complete coverage of pathology laboratories in 1990.81 In 
the Netherlands, cervical cancer screening became widespread 
after an extensive pilot project that started in 1976. Around 
1980, the program inviting women aged 35-53 with a 3-year 
interval reached an almost national coverage. However, much 
opportunistic screening in young women coexisted next to the 
organized program.163 In 1996, the program was reorganized. 
Women are since invited once every 5 years between ages 30 
and 60.56 In 2003, 77% of women at risk (=with a cervix) in this 
age group had at least one smear in the preceding 5 years.Chap-
ter 2 The most commonly used screening tool is a conventional 
Pap smear, although the share of liquid-based cytology smears 
is increasing.
In PALGA, women are identifi ed through their birth date 
and the fi rst four letters of the (maiden) family name. This iden-
tifi cation code enabled linkage of the tests belonging to the 
same woman, allowing following the individual screening and 
disease histories. Because this code is not always unique,127 we 
excluded women with 0.5% of the most common fi rst four letters 
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of the family name, i.e. about 30% of women.76 We identifi ed 
cervical cancer cases by (manually) checking the free text of the 
pathology reports for all excerpts that included pathology codes 
for cervical cancer. This was done for the period 1994-2002. The 
follow-up (person-years at risk and cases) in the present analy-
sis was therefore left-censored at the beginning of 1994 and 
right-censored at the end of 2002. 
Statistical analysis
We selected women in two age groups, 45-54 (“the older group”) 
and 30-44 (“the younger group”), if they had the third con-
secutive negative primary smear in this age interval at any time 
since the beginning of the registration. Women with prior histo-
logical (CIN 1+) or cytological (borderline dyskaryosis or worse) 
abnormalities were excluded. Women were followed-up from the 
date of the third negative smear until the date of the fi rst diag-
nosis of cervical cancer, or until end of 2002. We could not cen-
sor the follow-up in case of death from other causes because 
no information on the time of death was available. However, 
we estimate that the potential impact on our results was small 
because the female mortality rate in the Netherlands below age 
65 is low.164 
For both age groups, we fi rst calculated the cumulative inci-
dence rate (CIR) of cervical cancer in the period 1994-2002 by 
time since the third negative smear. Because for the majority of 
women, about 85% in the older and 80% in the younger group, 
at most 10 years of follow-up was available, we focused on the 
CIR during these fi rst 10 years. The difference in the CIR between 
the age groups was tested for statistical signifi cance assuming a 
Poisson distribution for the number of women with cancer, i.e. 
cases (H0: no difference in the CIR between the age groups). 
We estimated the 95% confi dence intervals using the non-para-
metric Kaplan-Meier product-limit estimator for log(hazard).155 
Second, the difference in the incidence rates between the two 
age groups during the whole period in follow-up (the hazard 
rate) was tested by Cox regression with left and right censoring. 
Time dependency of relative hazards was statistically tested by 
splitting the total follow-up time in two periods with a roughly 
equal number of cases.
4.4. Results
We identifi ed 219 thousand women in the older group and 445 
thousand in the younger group that met our inclusion crite-
ria (Table 4-1). The average interval between the 3 consecutive 
Table 4-1. The description of the study population, by 5-year age groups.
Age at entry
30-44 years 45-54 years
30-34 years 35-39 years 40-44 years 45-49 years 50-54 years
Number 126,748 156,435 162,199 124,254 94,593
CIR† 36 (23-58) 39 (26-59) 45 (32-61) 38 (22-66) 33 (21-53)
†Cumulative incidence rate per 100,000 women at 10 years after the third negative smear (95% CI).
Table 4-2. Incidence of invasive cervical cancer after the third consecutive negative smear for two age groups. Tabulated 
are woman-years,† number of invasive cancers, and the cumulative incidence rate of invasive cancer per 100,000 women 
(95% CI).
Age at entry
Time since the 
third negative 
smear
30-44 years 45-54 years P‡
Woman-years Women with 
invasive 
cancer
Cumulative 
incidence rate 
(95% CI)
Woman-years Women with 
invasive 
cancer
Cumulative 
incidence rate 
(95% CI)
Third negative 
smear
324,512 4 172,920 3
1 year 1 (0-3) 2 (1-5) 0.66
628,471 16 344,825 16
3 years 6 (4-10) 11 (7-17) 0.09
563,725 27 304,194 5
5 years 16 (12-21) 14 (10-21) 0.65
837,359 43 378,075 13
10 years 41 (33-51) 36 (24-52) 0.48
200,225 11 65,373 4
15 years 70 (51-95) 73 (39-135) 0.85
41,672 4 13,145 1
20 years 128 (79-207) 105 (50-219) 0.27
Total 2,595,964 105 1,278,532 42
CIR: cumulative incidence rate per 100,000 women. †Accrued between 1st January 1994 and 31st December 2002. ‡Two-sided, for 
difference in the CIR between the two age groups at specifi c time points.
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negative smears (i.e., between the fi rst and the second, and the 
second and the third smear) was 40 months in the older group 
and 39 months in the younger group. In the period between 1st 
January 1994 and 31st December 2002, 1.3 and 2.6 million per-
son-years in follow-up accrued in these women, respectively, an 
average of 5.84 and 5.83 years per woman (Table 4-2). The two 
groups had a similar rate of screening after the third negative 
smear (Table 4-3): about one third had none, about one third 
had one, and the remaining third had more than one further 
primary test registered. Forty-two women in the older, and 105 
women in the younger group developed cervical cancer (Table 
4-2).
During follow-up, the difference in the CIR between the age 
groups was never statistically signifi cant (Figure 4-1, and Table 
4-2). Pooling women into two large age groups does not seem to 
have affected this result, as the CIR at 10 years in smaller 5-year 
age groups also did not differ signifi cantly (Table 4-1; P=0.24). 
The overall hazard ratio was 0.84 (95% CI: 0.59-1.21) for 
the older compared with the younger group. The test for time 
dependency of the relative hazards was statistically non-signif-
icant (P=0.86).
We also calculated the CIR with CIN 1+ as the endpoint 
(Table 4-4, and Figure 4-2). By 10 years, the CIR was 12.6 (95% 
CI: 12.1-13.1) per 1,000 women in the younger group and 5.9 
(95% CI: 5.5-6.5) in the older group. The difference between 
both groups was statistically signifi cant throughout entire fol-
low-up. Using CIN 2+ or CIN 3+ as the endpoint instead of CIN 
1+ showed a similar relationship between the 
two age groups (data not shown).
4.5. Discussion
The risk for developing cervical cancer after 
the third consecutive negative smear among 
women around age 50 was practically the 
same as that among younger women (rela-
tive risk 16% lower, 95% CI: 41% lower to 21% 
higher). This outcome was not biased by dif-
ferential screening during follow-up because 
there was no difference between the age 
groups in this respect (Table 4-3). Evidence 
available in the literature does not show that 
either the screening sensitivity for high-grade 
CIN or the effectiveness of screening-induced 
CIN treatment substantially decreases with 
age.38, 45, 165-167 Therefore, it is reasonable to 
assume that after several consecutive nega-
tive smears the screening effi ciency in terms 
of detection and prevention of cervical cancer 
is at the same level around age 50 as it is at 
younger ages.
We observed a lower risk for CIN 1+ in the 
older group (Table 4-4 and Figure 4-2). In this 
respect, our data is consistent with that of 
others.90, 92, 95, 97 This corroborates that CIN is 
not an accurate intermediate endpoint for the 
question addressed. 
Because women were included as soon 
as they had the third consecutive negative 
smear, younger women will on average have 
been screened more intensely than older 
women; the latter may therefore be at higher risk. However, 
the selection criterion of being disease-free on 3 consecutive 
screenings, and the fi nding that the screening attendance after 
the third negative smear was similar in both groups, make such 
a bias unlikely. We tested this in an additional analysis, where 
we included women from the younger group also in the older 
group if they continued to have negative smears after age 44. 
The result was the same: the 10-year CIR in the older group in 
this case slightly decreased from 36 (95% CI: 24-52) to 34 (25-
48) per 100,000.
The similarity in the CIR between the two age groups is not 
unexpected given the observed age-specifi c incidence before 
screening became widespread2 (i.e. before ca. 1970 in most devel-
oped countries). In the Netherlands, as well as in several West-
ern-European countries, the pre-screening incidence rose rapidly 
until a peak around ages 44 to 49 years, and declined thereafter. 
This would translate into roughly equal levels of CIR during the 
fi rst 10 years for the two age groups. In some other countries, 
like the UK and the USA, the decline in the pre-screening inci-
dence at older ages is slower. If this pattern is due to a truly dif-
ferent age effect and not to a cohort effect, the cancer incidence 
reduction gained through continued screening in the older group 
would be even relatively higher than in the Netherlands.
The question of age-specifi c screening effi ciency can be fur-
ther explored by comparing the average number of life-years lost 
in absence of screening. Younger women have a longer remain-
ing life expectancy than older women, but they also have lower 
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Figure 4-1. The cumulative incidence rate for invasive cancer, by age group 
and time since the third consecutive negative smear.
Table 4-3. Screening intensity: Number of primary screening tests after 
the third consecutive negative smear. Average number of years at risk for 
further smears after the third negative smear were 6.7 years and 6.4 years 
among women aged 30-44 and 45-45, respectively. 
Age at entry
Number of primary screening tests 
after the 
third negative smear 30-44 years 45-54 years
0 35% 35%
1 27% 33%
2 18% 18%
3 10% 8%
≥4 10% 7%
Total 100% 100%
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lethality rates from cervical cancer. The remaining female life 
expectancy in the Netherlands is 42, 33 and 24 years at ages 40, 
50 and 60, respectively,168 while the 5-year mortality rate from 
clinical cervical cancer increases from 50% to 70% and 75%, 
respectively, at the same ages.169 Assuming that the 5-year mor-
tality rates approximate the total lethality, around 20 years are 
lost per incident case for all 3 ages, which means that decreasing 
life expectancy and the increasing cancer lethality compensate 
each other. At even older ages, however, the number of life-years 
lost per incident case starts to decrease. 
Our data does not permit a simple extension of our study to 
older ages. For example, in 79,586 women satisfying the criteria 
at ages 55 to 64 years, the 10-year CIR was 47 per 100,000 (95% 
CI: 23-99), and was statistically comparable to that in women 
below age 55. However, women aged 55-64 years had a consid-
erably lower screening intensity after the third negative smear: 
60% had no further smear compared with 35% in women below 
age 55. In women above 64, screening intensity decreases even 
further. This diminishes the actual comparability of women aged 
55 or older with women below that age, and as a consequence, 
a clear conclusion on the relative screen-
ing effi ciency cannot be drawn. 
We selected women with negative 
screening histories, i.e. women who 
never had cytological or histological evi-
dence of neoplasia. In everyday prac-
tice, though, complete screening his-
tories may not always be known and 
may contain abnormalities. Women with 
prior abnormalities, i.e. at least abnor-
mal cytology, remain at higher risk for 
invasive cancer despite later consecutive 
negative smears.170 In our data, inclusion 
of women with screen-detected abnor-
malities followed by 3 consecutive pri-
mary negative smears does not affect the 
two age groups differently: the CIR at 10 
years is 42 (95% CI: 30-57) per 100,000 
women in the older and 42 (34-51) in the 
younger group. 
The continued risk for cervical can-
cer is consistent with the considerable 
incidence of HPV infections in older 
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Figure 4-2. The cumulative incidence rate for CIN 1+, by age group and time since 
the third consecutive negative smear.
Table 4-4. Incidence of CIN after a third consecutive negative smear for two age groups. Tabulated are woman-years,† 
number of CIN 1+, a cumulative incidence rate of CIN 1+ per 100,000 women (95% CI).
Age at entry
Time since the 
third negative 
smear
30-44 years 45-54 years P‡
Woman-years Women with 
CIN 1+
Cumulative 
incidence rate 
(95% CI)
Woman-years Women with 
CIN 1+
Cumulative 
incidence rate 
(95% CI)
Third negative 
smear
324,381 233  172,850 90   
1 year   72 (63-82)   52 (42-64) 0.008
627,524 584  344,441 172   
3 years   258 (241-277)   152 (135-172) <0.001
561,412 834  303,363 240   
5 years   555 (529-583)   310 (284-339) <0.001
829,336 1,192  375,786 224   
10 years   1,258 (1,209-1,308)   594 (547-645) <0.001
196,753 197  64,635 30   
15 years   1,707 (1,622-1,796)   769 (686-862) <0.001
40,898 24  12,995 5   
20 years   1,986 (1,841-2,143)   920 (772-1,096) <0.001
Total 2,580,304 3,064  1,274,070 761   
†Accrued between 1st January 1994 and 31st December 2002. ‡Two-sided, for difference in the CIR between the two age groups at 
specifi c time points.
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women.171, 172 When primary screening would be done by HPV 
testing, our conclusions would therefore remain the same. This 
would also mean that the HPV vaccine may only succeed in 
attaining its full potential of eradicating up to 70% of cervi-
cal cancer if it offers protection from a persistent HPV infection 
for many decades, i.e. also after age 50. This again will depend 
strongly on the – unknown – proportion of infections around and 
after age 50 that are due to reactivated latent infections acquired 
earlier in life.173, 174 
By being able to use invasive cancer as the relevant end-
point, our analysis gives a more evidence-based answer to the 
on-going discussion on continued screening in women with sev-
eral negative smears by age 50. It showed that it would not be 
consistent to stop screening in these women while not relaxing 
the screening policy for women with similar screening histories 
at younger age. In this respect, our conclusion lends support to 
the current cervical cancer screening guidelines in England and 
other developed countries,111, 175-178 which do not discriminate 
women by their age up to 60 to 65 years. 
Whether individual tailoring of recommendations for further 
screening by using the information on individual screening his-
tories would be an effi cient and feasible alternative in any age 
group to the current fi xed schedule, remains to be explored. 
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5.1. Abstract
Objective. We aimed to obtain large-scale and generalizable data 
on the long-term predictive values of cytology and Human Pap-
illomavirus testing for development of cervical intraepithelial 
neoplasia grade 3 or cancer. Design. Multinational cohort study 
with joint database analysis. Setting. Seven primary Human Pap-
illomavirus screening studies in 6 European countries. Partic-
ipants. 24,295 women attending cervical screening who were 
enrolled into Human Papillomavirus screening trials and had at 
least 1 cervical cytology or histopathology during follow-up. 
Main outcome measure. Long-term cumulative incidence rate of 
cervical intraepithelial neoplasia grade 3 or cancer. Results. The 
cumulative incidence rate of cervical intraepithelial neoplasia 
grade 3 or cancer after 6 years was considerably lower among 
Human Papillomavirus-negative women (0.27% (95% CI: 0.12-
0.45%)) than among cytology-negative women (0.97% (95% CI: 
0.53-1.34%)). By comparison, the cumulative incidence rate of 
cervical intraepithelial neoplasia grade 3 or cancer for cytology-
negative women at the most commonly recommended screening 
interval in Europe (3 years) was 0.51% (95% CI: 0.23-0.77%)). 
The cumulative incidence rate of cervical intraepithelial neo-
plasia grade 3 or cancer among cytology-negative/Human Pap-
illomavirus-positive women increased continuously over time, 
reaching 10% at 6 years, whereas the cumulative incidence rate 
of cervical intraepithelial neoplasia grade 3 or cancer among 
cytology-positive/Human Papillomavirus-negative women 
remained below 3%. Conclusions. A consistently low 6-year 
cumulative incidence rate of cervical intraepithelial neoplasia 
grade 3 or cancer among Human Papillomavirus-negative women 
suggests safety of cervical screening strategies with Human Pap-
illomavirus testing at 6-yearly intervals. 
5.2. Introduction
Cytological screening has reduced cervical cancer incidence in 
countries with organized screening179 but there were still an 
estimated 68,000 incident cases in Europe in 1995.180 Cytol-
ogy has limited reproducibility181 and both meta-analyses and 
pooled analyses of cross-sectional studies have established that 
Human Papillomavirus (HPV) tests have higher sensitivity than 
cytology in detecting high-grade cervical intraepithelial lesions 
(CIN)46, 48 and that combined HPV and cytology testing has very 
high negative predictive values for CIN.182-184 However, cost-
effectiveness modeling of screening strategies is highly depen-
dent on reliable and generalizable estimates of the longitudinal, 
long-term predictive values of testing. The long-term nega-
tive predictive value (NPV) is the main determinant of the safe 
screening interval to use, a key factor for the cost-effi ciency of 
a screening program. The long-term positive predictive value 
(PPV) is an important measure of the extent of unnecessary 
procedures induced by screening, another major factor in cost-
effi ciency evaluations. As low and moderate grades of CIN often 
regress, predictive values to be used for modeling should ideally 
use CIN grade 3 or cancer (CIN3+) as the outcome.12 
Several randomized controlled trials are currently being 
conducted to compare HPV-based primary screening with con-
ventional cytology screening.98, 99, 185-189 Data from these trials 
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indicate that HPV-based screening results in detection of more 
high-grade CIN lesions (a higher sensitivity) but a reduced 
specifi city compared to cytology-based screening. The random-
ized trials found that the increased sensitivity for CIN3+ is not 
merely overdiagnosis as there is a correspondingly lower CIN3+ 
incidence in the future,98, 99, 185, 186 further establishing the 
validity of using CIN3+ as endpoint in studies of HPV-based cer-
vical screening.
However, most of the cohort studies and the randomized tri-
als have observed only limited numbers of CIN 3+ cases on lon-
ger term follow-up, resulting in limited statistical power for esti-
mating the critical factor for deciding the appropriate screening 
interval: the CIN3+ rate among screen-negative women. Further-
more, clinical and diagnostic practices vary between European 
countries and different studies have often used different meth-
ods for evaluation, making meta-analyses diffi cult.
To obtain large-scale and generalizable data on long-term 
CIN3+ predictive values, seven HPV screening studies in six EU 
countries, each investigating the predictive value of primary 
HPV screening for future CIN3+, supplied primary data to a com-
mon database for joint statistical analysis. Variability between 
studies was assessed and the overall long-term predictive values 
for CIN3+ estimated. 
5.3. Material and Methods
The seven prospective HPV studies in six European countries 
that supplied the data to the common database for joint statis-
tical analysis were designed to evaluate primary cervical screen-
ing using HPV testing. The design of the seven studies, inclusion 
and exclusion criteria, setting and location is summarized in 
Table 5-1. All studies used routine cytology as currently prac-
tised in their country. The different HPV tests used are listed in 
Table 5-1 and further described for each country below. For all 
studies the persons executing either test were unaware of the 
results of the other test. Comparability and reproducibility of 
the 2 major HPV tests used (Hybrid Capture 2 and GP5+/6+ poly-
merase chain reaction (PCR)) was evaluated using kappa statis-
tics.190 All studies were approved by the Ethical Review Boards 
in their respective countries. Recruitment was consecutive and 
data collection prospectively planned. 
Denmark
Women in the general population were enrolled in a prospective 
cohort study of the natural history of HPV and cervical neo-
plasia between 1993-95. They were interviewed and a cervical 
smear for cytology and cervical swabs for HPV DNA detection 
using Hybrid Capture 2 (HC 2) were taken.191 In Denmark, every 
citizen has a unique 10-digit personal identifi cation number 
that was linked to the national Pathology Data Bank (a nation-
wide computerized pathology register containing all cytologi-
cal and histological diagnoses in Denmark) to allow follow-up. 
Data from women with double negative tests were supplied to 
the joint database. 
Germany – Hannover and Tuebingen studies
In 1999-2000 women 30 years or older were invited to the medi-
cal universities in Hannover or Tuebingen for a prospective 
cohort study (HAT-trial) on HPV screening among women 30 
years or older.183 In Hannover women were followed with col-
poscopy every 6-12 months if they had a positive HC 2 test 
or positive cytology at baseline. Double negative women were 
followed with annual Pap smears and in addition, 5 % of the 
women with a double negative test result were referred for col-
poscopy fi ve years later. In Tuebingen, patients with a double 
negative result at baseline were followed up with cytology and 
HC 2 test after 5 years and if either test was positive they were 
referred for colposcopy.
United Kingdom 
The UK study was based on women attending routine screening 
in West London to evaluate HPV-based screening in women aged 
35 or over during 1994-1997.16 DNA analysis was initially per-
formed using the PCR/SHARP system detecting HPV types 16, 18, 
31, 33, 54, 51, 52, 56 and 58 and women with a positive HPV test 
or abnormal cytology were referred for colposcopy. The samples 
were retrospectively analysed using HC 1 for the fi rst half of the 
study and by HC 2 for the second half of the study. HPV results 
reported in our analyses are based on Hybrid Capture results. All 
women were followed-up using the National Health Service com-
puterised call/recall system which records all smears and their 
results. In addition, all women were invited to and 520 women 
attended a follow-up visit with HPV test and colposcopy. 
France
Women who participated in biennial or triennial routine screen-
ing from 1997 to 2002 in Reims, France, were invited to partici-
pate in a study to evaluate HPV testing (HC 2) in cervical cancer 
screening.192 All women with abnormal cytology were referred 
for colposcopy. Women with a positive HPV test but normal 
cytology were recalled after 6-12 months for a repeat cytological 
smear and HPV test. If a cytological abnormality was found or if 
the women had a persistent HPV infection she was referred for 
colposcopy. Women with normal cytology and a negative HPV 
test at baseline were followed with standard biennial or trien-
nial cervical screening. A random 15% of baseline double nega-
tive women were also referred for colposcopy.
Sweden
Between 1997 and 2000, women aged 32-38 years who took part 
in organized cervical screening in fi ve regions of Sweden (Goth-
enburg, Malmö, Stockholm, Umeå and Uppsala) were invited 
to participate in a randomized population-based trial of pri-
mary HPV screening using general primer GP5+/6+ PCR.193 In 
the intervention arm, HPV positive women were invited for a 
second cytology and HPV test at least a year later, together 
with a similar number of women randomly selected from the 
control arm. Women with persistent HPV infection, as well as 
a similar number of women from the control arm, were invited 
for colposcopy.193 Women with abnormal cytology were referred 
for colposcopy in accordance with established clinical algo-
rithms. All women in the intervention arm and the randomly 
selected women from the control arm are included in this paper. 
All study participants were followed by registry linkages with 
comprehensive regional cytology and pathology registries using 
unique personal identifi cation numbers. 
Spain
During 1997 to 2001,194 women were enrolled who were either 
randomly selected from the general population of the Barcelona 
metropolitan area or were attending 9 family planning clinics 
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for routine screening. Both enrolment strategies performed fre-
quency matching to the underlying general population. The 
aims of the study were to estimate the incidence and prevalence 
of genital HPV infection and to evaluate the predictive value 
of cytology and HPV testing for future CIN at 1 and 5 years 
follow-up. HPV testing was done by means of HC2. Women from 
the general population were referred for colposcopy if there was 
an abnormal cervical cytology or if there was a persistent HPV 
positive test at the end of follow-up. The women from the fam-
ily planning clinics were referred for colposcopy if there was an 
abnormal cervical cytology or if there were two consecutively 
positive HPV tests. 
Statistical analysis
From the joint cohort, only women with adequate cytology 
and HPV test at baseline, and with at least one follow-up cyto-
logical or histological test were included in the present analy-
sis. In the analysis of the joint cohort, abnormal cytology was 
regarded as the equivalent of atypical squamous cells of uncer-
tain signifi cance (ASCUS) or worse for all participating studies. 
Women were followed from the date of the baseline test. Inci-
dence is dependent on the number of person-years of follow-up 
time and for a screen-detectable disease follow-up requires hav-
ing attended screening. Therefore, follow-up was censored at 
the date the CIN3+ lesion (CIN 3 or invasive cancer, including 
squamous and adenocarcinoma) was diagnosed, or at the last 
registered testing date. 
First, the country-specifi c estimates of the cumulative inci-
dence rate (CIR) of CIN 3+ by original baseline group (cyt-/
HPV-, cyt-/HPV+, cyt+/HPV- and cyt+/HPV+) were estimated; 
their 95% confi dence intervals (CI) were estimated using the 
non-parametric Kaplan-Meier product-limit estimator for 
log(hazard).155 Second, whether the inhomogeneity between the 
different studies in the joint cohort is a major factor infl uencing 
results can be tested for by comparative analysis of systemati-
cally drawn subsamples of the joint cohort, so-called bootstrap 
analysis.195 The bootstrap stratifi ed random subsample was con-
structed by drawing, with replacement, fi rst from studies and 
then from individuals within studies. 1,000 bootstrap replicas 
were constructed and analysed analogous to the original coun-
try-specifi c analysis. The mean of these 1,000 replicas was used 
as the pooled estimate of the CIR corrected for heterogeneity, 
and 2.5 and 97.5 percentiles as estimates for the 95% CI. As 
a measure for heterogeneity, the original cohort-specifi c 95% 
confi dence intervals were compared with those obtained by the 
multilevel bootstrap. This can be transformed into an estimate 
of the over-dispersion parameter (or “scale” parameter), where 
the value 1.00 points to no heterogeneity among the studies 
and values >1.00 point to increasing levels of heterogeneity.196, 
197 Third, we calculated the test performance indices for cytol-
ogy alone, HPV test alone and cytology and HPV test combined 
(at least one of the two positive). Because data was not com-
plete for all 4 original baseline groups, studies from Denmark 
and Tuebingen were excluded from these analyses. These indices 
were calculated using 2×2 tables based on the CIR at 72 months 
for the different baseline test combinations, weighted by the 
proportion (adjusted for heterogeneity) of each of these sub-
groups at baseline.198 The 95% confi dence intervals around the 
indices were obtained by bootstrap.196 All analyses used S-PLUS 
6.0 Professional Release 1. 
Role of the funding sources 
None of the funding sources had any involvement in study 
design; in the collection, analysis, and interpretation of data; in 
the writing of the report or in the decision to submit the paper 
for publication.
5.4. Results
Out of 24,295 women included in the pooled analyses, 381 devel-
oped histologically confi rmed CIN3+ during 6 years of follow-up 
(Table 5-2). The positive predictive value for future CIN3+ was 
highest among women with baseline abnormal cytology and 
positive HPV test (cyt+/HPV+) (CIR: 34 %, 95% CI: 26.8-45.4%) 
(Figure 5-1). Women with normal cytology but positive HPV test 
(cyt-/HPV+) had a continuously increasing CIR of CIN3+, even-
tually reaching 10 % (95% CI: 6.2-15.1%) after 6 years. Women 
with abnormal cytology and negative HPV test (cyt+/HPV-) had 
a CIR for CIN3+ of 2.7 % (95% CI: 0.6-6.0%). Women with both 
normal cytology and negative HPV test (cyt-/HPV-) had a very 
low risk of future CIN3+ (CIR: 0.28 %, 95% CI: 0.10-0.47%). The 
CIR of CIN3+ after being cyt-/HPV- was compared to the CIR of 
CIN3+ for normal cytology alone and negative HPV test alone 
(Figure 5-2). At 6 years of follow-up, the CIR of CIN3+ was sig-
nifi cantly lower among HPV-negative women (0.27% (95% CI: 
0.12-0.45%) than among cytology-negative women (0.97% (95% 
CI: 0.53-1.34%). By comparison, the CIR of CIN3+ at the most 
commonly recommended screening interval in Europe (3 years) 
was 0.51% (95% CI: 0.23-0.77%) for cytology-negative women 
and 0.12% (95% CI: 0.03-0.24%) for HPV-negative women. 
At 5 and 4 years of follow-up, the CIRs were 0.25% (95% CI: 
0.12-0.41%) and 0.19% (95% CI: 0.08-0.32%) for HPV-negative 
women compared to 0.83% (95% CI: 0.50-1.13%) and 0.69% 
(95% CI: 0.39-0.98%) for cytology-negative women. There was 
very little difference in CIR for CIN3+ between double negative 
and HPV-negative women (Figure 5-2). The CIR for CIN3+ among 
HPV-positive women was lower than for women with abnormal 
cytology, but increased continuously and gradually approached 
the CIR of cytology-positive women (Figure 5-3). 
Table 5-2. Number of women in the analysis, and the number of CIN 3+ diagnosed within 6 years of baseline.
Baseline group Number of women at 
baseline†
Number of women still in follow-up after: Number of women 
with CIN 3+60 months 72 months
Cyt-/HPV- 21,060 7,019 4,571 32
Cyt-/HPV+ 1,962 268 111 107
Cyt+/HPV- 436 89 46 10
Cyt+/HPV+ 837 67 40 232
Total 24,295 7,443 4,778 381
†With at least one cytology or histology follow-up.
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Figure 5-1. Kaplan-Meier plots of CIR for CIN 3+ for women who were cyt-/HPV-, cyt-/HPV+, cyt+/
HPV-, and cyt+/HPV+ at baseline, in the fi rst 72 months of follow-up. All 7 countries.
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Figure 5-2. Kaplan-Meier plots of CIR for CIN 3+ for women who were cyt-, HPV-, and cyt-/HPV- at 
baseline, in the fi rst 72 months of follow-up. Denmark and Tuebingen excluded.
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Analysis using an alternative outcome defi nition that 
included all high-grade lesions (CIN grade 2 or worse; CIN2+) 
found essentially similar results, but based on a higher num-
ber of cases (n=585). E.g., at 6 years of follow-up, the CIR of 
CIN2+ was 0.67% (95% CI: 0.39-1.11%) among HPV-negative 
women and 1.76% (95% CI: 1.00-2.47%) among cytology-nega-
tive women. The CIR of CIN2+ at 3 years of follow-up was 0.79% 
(95% CI: 0.43-1.16%) for cytology-negative women and 0.19% 
(95% CI: 0.07-0.38%) for HPV-negative women.
As the prevalence of HPV infection is highly age-dependent 
and since cytological performance also varies with age, we ana-
lysed PPV, NPV, sensitivity and specifi city of the screening tests 
stratifi ed by age group (Table 5-3). The sensitivity and NPV of 
cytology improved as women became older (Table 5-3). Both 
cytology and the HPV test had higher specifi city for women 
above 35 years of age, but did not improve any further among 
women above 49 years of age (Table 5-3).
The seven studies included in the pooled analyses had 
estimates of CIR for CIN3+ that were not signifi cantly differ-
ent among cyt-/HPV-, cyt-/HPV+ or cyt+/HPV- women (scale 
parameters: 2.48, 1.80, 2.23; P-values: 0.14, 0.36, 0.1). How-
ever, the CIR of CIN3+ among women with positive cytology and 
HPV-test was clearly different between studies (scale parameter 
4.77; P=0.01) (Figure 5-4).
5.5. Discussion
Using pooled data from seven HPV screening studies in six 
European countries we made a European estimate of the CIR 
for future histologically confi rmed CIN3+ during 6 years of fol-
low-up. The uniformly low CIR among cyt-/HPV- women sug-
gests that double negativity confers a long-lasting protective 
effect that is remarkably robust, considering that the partici-
pating studies used several different types of HPV tests in sev-
eral different settings and in several different age groups. The 
long-lasting protective effect was similarly low for HPV-negative 
women as for double negative women. 
The fact that several studies in different settings in differ-
ent countries and with different infrastructure and intensity of 
follow-up gave largely similar results is a strength of the study, 
as it implies that the data is generalizable to a variety of dif-
ferent settings. Similarly, the fact that the actual cytology tests 
and actual HPV tests that are being used in the different coun-
tries were studied implies that the data is generalizable. E.g., 
the largest study in the joint cohort (France) used the most 
modern cytology technique (liquid-based cytology) and the sev-
eral other cohorts used the same routine conventional cytology 
as is being used in organised programs with documented cancer-
preventive effect.
Our results are well in line with the results from a US cohort 
of 20,810 women that found that cyt-/HPV- women had a cumu-
lative incidence of CIN3+ of 0.16 % after 45 months and 0.79 % 
after 122 months.184 Similarly, a German cohort of 4,034 women 
reported that 0.7% of cyt-/HPV- developed CIN3+ during 5 years 
of follow-up182 and a Dutch cohort of 2,810 women found only 
1 case of CIN3+ among double negative women during 4.6 years 
of follow-up.199
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Figure 5-4. Comparison of CIN 3+ incidences at 60 months 
by country and by baseline test results.
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As expected, the HPV test was less specifi c than cytol-
ogy. The higher specifi city above 35 years of age suggests that 
restricting HPV testing to older women would reduce overdiag-
nosis. However, with increasing length of follow-up the CIR for 
CIN3+ increased more among HPV-positive women than among 
cytology-positive women. This implies that the problem of 
HPV-based screening resulting in increased overdiagnosis with 
women unnecessarily referred to clinical procedures is attenu-
ated in evaluations with longer follow-up – some of the HPV 
positivity that appears to be false positivity in cross-sectional 
evaluations will turn out to be true, but earlier, detection of 
CIN 3+ cases. 
Verifi cation bias may overestimate the performance of 
screening tests when only women with a positive screening test 
are referred to colposcopy. Only some of the included studies 
performed colposcopies of double-negative women. However, 
it is rare to diagnose CIN3+ by colposcopy of double-negative 
women187, 200 and the fact that there was limited variability 
between studies also suggests that verifi cation bias has not 
materially affected our estimates. 
Nevertheless, as assessment of the CIN3+ incidence by base-
line group during follow-up is dependent on the screening 
intensity our estimates should be interpreted as relative rather 
than absolute.201 However, we only included women who had 
been screened at least once during follow-up and the follow-up 
time was longer than the recommended screening intervals in all 
the included studies.111 
In one study (Spain), there was no action taken because of 
positive baseline HPV tests whereas four studies mandated extra 
testing and/or colposcopy after baseline HPV-positivity (Swe-
den, Hannover, UK and France). As Denmark and Tuebingen are 
not included in the follow-up of cytology-positive or HPV-posi-
tive women, the CIR of CIN3+ presented in this study are almost 
entirely based on active follow-up of HPV-tests and should 
refl ect the outcome of active HPV-based screening strategies. 
As CIN3+ prevalence is associated with HPV prevalence it is 
possible that some heterogeneity between studies is explained 
by differences in HPV prevalence e.g. Spain has been reported 
to have a low prevalence of HPV.194 Another possible source of 
variability is the fact that the German, French, Danish, British 
and Spanish studies used HC2 for HPV detection while the Swed-
ish study used PCR. The agreement of HC2 and PCR has been 
reported to be substantial202, 203 and there was also no obvious 
difference in results depending on the HPV test used. The most 
obvious source of heterogeneity between countries was the vari-
ability in Pap smear interpretation, as the proportions of cytol-
ogy positives ranged from 2% (Sweden) over 4% in Hannover 
and Spain to 5% in the UK and 7% in France; these differences 
cannot be entirely explained by the observed differences in the 
HPV prevalence.
In conclusion, we have provided joint European data sug-
gesting that screening intervals could safely be lengthened to 
6 years among women with a negative HPV test. This could at 
least partly compensate for the increased referral rate resulting 
from HPV-based screening strategies.
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6.1. Abstract
In the Netherlands 2% of cervical smears in the cervical cancer 
screening program are read as borderline or mildly dyskaryotic 
cytology (BMD smear). Only in about 10% of these women a 
high-grade CIN lesion (CIN 2-3) is present, therefore referral is 
for the majority unnecessary. In this study triage with high-
risk HPV (hrHPV) testing was used to identify women at risk 
for development of high-grade CIN lesions after a repeat BMD 
smear. A ”wait-and-see” period was incorporated allowing clear-
ance of HPV and regression of the lesion. Women with a low-
grade lesion, irrespective of their HPV-status were monitored at 
12 months; women with a high-grade lesion at 6 and 12 months. 
Fifty-one of the 105 women (49%) were hrHPV negative at base-
line, none of them showed progression of the lesion within the 
fi rst year of follow-up (NPV 100%). High-grade CIN was present 
in one patient who was HPV negative at baseline (2%), she dem-
onstrated regression after 12 months. Nineteen of the hrHPV 
positive women (35%) demonstrated a high-grade CIN lesion 
at baseline, three cleared hrHPV after 6 months, with a subse-
quent regression of CIN. Ten women remained hrHPV positive 
with persistence of high-grade CIN and were eventually treated. 
At baseline 35 hrHPV positive women demonstrated a low-grade 
lesion, 19 remained hrHPV positive after 12 months, 5 devel-
oped high-grade CIN. Sixteen out of the 35 cleared the hrHPV 
infection without progression of the lesion. In conclusion, tri-
age using hrHPV testing for women with persistent BMD cytol-
ogy can select women who are not at risk for development of 
high-grade CIN. We recommend return to the screening program 
without referral for colposcopic examination if hrHPV is absent. 
For hrHPV positive women a repeat hrHPV test after another six 
months is suggested. Referral is only required if persistence of 
hrHPV is established.
6.2. Introduction
In the Dutch population-based cervical cancer-screening pro-
gram women between 30 and 60 years of age undergo a cyto-
logical smear every fi fth year. Recent surveys showed that about 
2% of these smears contained borderline or mildly dyskaryotic 
(BMD) changes.15, 60 According to current screening guidelines, 
in these cases cytology is repeated after 6 months and (if neg-
ative) after 12 months. When cytology is persistently abnor-
mal, women are referred to the gynaecologist where colposcopic 
examination is performed and a biopsy is taken for histologi-
cal examination. When histology shows no or low-grade dyspla-
sia (≤CIN 1) women will be kept under cytological surveillance 
without immediate treatment. High-grade dysplasia (CIN 2-3) or 
a worse lesion will be treated. Only ten percent of women with 
a single BMD smear show a high-grade CIN lesion.37, 41, 204, 205 
Consequently, there is a need for an improved risk assessment 
of women with BMD. 
Infection with high-risk HPV (hrHPV) has been established 
as an important etiological factor in the carcinogenesis of cer-
vical cancer.5, 8 Persistence of hrHPV infection is required for 
development of cervical cancer.25, 27, 191, 206 Several studies have 
shown that HPV testing has a high sensitivity (approximately 
95%) for identifying high-grade lesions and cervical carcinoma. 
Moreover, the negative predictive value of HPV testing for detec-
tion of a high-grade CIN lesion or even (micro) invasive carci-
noma is nearly 100%.101, 207 Consequently, HPV-testing may play 
an important role in clinical practice, i.e. in triage of women 
with BMD cytology, as an adjunct to cytology in primary screen-
ing and in post-treatment protocols.208-210 
The prevalence of hrHPV in women with BMD smears is about 
35%211, 212 and it is likely that hrHPV negative BMD women are 
not at risk for development of high-grade CIN lesions or carci-
noma. Hence, triage with hrHPV testing may improve the selection 
CHAPTER 6. Triage Using HPV-testing in 
Persistent Borderline and Mildly Dyskaryotic 
Smears: Proposal for New Guidelines
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2Department of Public Health, Erasmus MC, Rotterdam, the Netherlands
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of women at risk for development of cervical cancer and conse-
quently the management of women with BMD smears.44, 106, 209, 211, 
213, 214 This would not only have the advantage of improving the 
effi ciency of the screening program through fewer referrals, but 
also reduce unnecessary anxiety among the majority of women 
with BMD who are not at risk for high-grade CIN.204, 205, 215 
In this prospective study, triage with hrHPV testing was per-
formed in the follow-up of women referred with a repeated BMD 
established in the screening program. Unlike most published 
studies a wait-and-see period was incorporated in the present 
protocol to allow potential clearance of hrHPV infection and 
consequently regression of the cervical lesion. We evaluated the 
use of triage with hrHPV testing to prevent unnecessary diag-
nostic procedures and treatment. 
6.3. Material and Methods
All women with a repeated BMD smear referred through the 
national screening program to gynaecological outpatient clinics 
were asked to participate in this study. Participating hospitals 
were the Erasmus University Medical Centre Rotterdam (Decem-
ber 1999 - May 2003), the Hospital Walcheren in Vlissingen (Jan-
uary 2000 - March 2002) and the VU University Medical Center 
Amsterdam (June 2000 - January 2003). Exclusion criteria were 
pregnancy at time of enrolment or during follow-up (n=3), non-
Hodgkin lymphoma (n=1), age younger than 30 years or older 
than 60 years at time of abnormal smear (n=5), or insuffi cient 
Dutch or English language skills (n=1). 
Figure 6-1 shows the trial design. At baseline women were 
asked to complete a questionnaire on education, ethnic back-
ground, smoking, number of sexual partners, sexarche, contra-
ceptive use and history of sexually transmitted diseases. A cer-
vical scrape was taken for HPV detection followed by colposcopy. 
Standard colposcopical assessment with acetic acid and iodine 
solution was performed by expert gynaecologists. Biopsies were 
taken from all colposcopic abnormalities. At this fi rst visit no 
treatment was carried out. 
Figure 6-1.  (1 panel)
 
 
 
 
 
 
 
 
 
 
 
  
 
Two times BMD smear 
Referral to gynaecologist 
n=115 
Non-eligibility – end of study 
n=10 
HPV-testing / Colposcopy 
n=105 
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n=54 
 CIN 1 
n=35 
CIN 2-3 
n=19 
After 6 months:  
HPV testing, colposcopy 
hrHPV positive 
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hrHPV negative
n=3 
 CIN 1 
n=3 
CIN 2-3 
 
 CIN 1 
n=6 
CIN 2-3 
n=10 
Treatment  
End of study 
hrHPV negative 
n=51 
 CIN 1 
n=50 
CIN 2-3 
n=1 
After 12 months: 
HPV-testing, cytology, colposcopy
Figure 6-1. Trial design.
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Women who were hrHPV negative were reviewed after 12 
months. HrHPV positive women were reviewed after 12 months if 
the colposcopically-directed biopsy was ≤CIN 1, and after 6 and 
12 months if histology showed moderate to severe dysplasia (CIN 
2-3). During follow-up visits hrHPV-testing and colposcopy were 
performed. Women with a persistent hrHPV-positive high-grade 
CIN lesion during follow-up were treated by loop excision of the 
transformation zone (LETZ). The study endpoint was reached after 
12 months, or after treatment, whichever came fi rst. The study 
protocol was approved by a multicenter research ethics commit-
tee and by local committees at all three hospitals. All women vol-
untarily gave signed informed consent before enrolment.
Histology
Lesions were histologically defi ned as mild dysplasia (CIN 1), 
moderate dysplasia (CIN 2), severe dysplasia (CIN 3) and (micro) 
invasive cancer. Lesions ≤CIN 1 are hereafter referred to as a 
low-grade lesion and CIN 2-3 as a high-grade lesion. Regression 
or progression was defi ned as histological change from a high-
grade lesion to low-grade lesion or vice versa, detected in the 
biopsy material at two consecutive time points as scheduled by 
the trial design. All histological samples were read by expert 
pathologists. 
Human papillomavirus testing 
All HPV samples were taken by a cervical biosampler (Accellon 
Combi® Medscand Medical, Sweden). Testing for HPV was con-
ducted by using a general/consensus primer based GP5+/ GP6+ 
polymerase chain reaction (PCR) enzyme immunoassay (EIA) for 
14 high risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66 and 68).216 This test has been clinically validated.206, 
217, 218 Additionally, reverse line blot (RLB) analysis was used 
Table 6-1. Baseline characteristics.
Total hrHPV negative hrHPV positive Signifi cance
n=105 (100%) n=51 (100%) n=54 (100%)
Age at intake (years)† P<0.01
30-40 58 (55%) 17 (33%) 41 (76%)
40-50 26 (25%) 16 (31%) 10 (19%)
50-60 21 (20%) 18 (35%) 3 (6%)
Histology at intake† P<0.01
Low-grade 85 (81%) 50 (98%) 35 (65%)
High-grade 20 (19%) 1 (2%) 19 (35%)
Ethnic background
Caucasian 82 (78%) 43 (84%) 39 (72%)
Asian 4 (4%) 2 (4%) 2 (4%)
Negroid 10 (10%) 4 (8%) 6 (11%)
Mediterranean 4 (4%) 0 4 (7%)
Other 5 (5%) 2 (4%) 3 (6%)
Education
Primary or less 9 (9%) 4 (8%) 5 (9%)
Secondary, incomplete 55 (52%) 32 (63%) 23 (43%)
Secondary or more 41 (39%) 15 (29%) 26 (48%)
Age at fi rst intercourse (years)
≤15 23 (22%) 8 (16%) 15 (28%)
16-18 51 (49%) 26 (51%) 25 (46%)
≥19 31 (30%) 17 (33%) 14 (26%)
No. of sexual partners last year
0-1 89 (85%) 45 (88%) 44 (81%)
2-4 16 (15%) 6 (12%) 10 (19%)
Smoking
No 56 (53%) 32 (63%) 24 (44%)
Yes 49 (47%) 19 (37%) 30 (56%)
Oral contraceptive use
No 62 (59%) 34 (67%) 28 (52%)
Yes 43 (41%) 17 (33%) 26 (48%)
History of Sexually Transmitted disease† P<0.01
No 84 (80%) 48 (94%) 36 (67%)
Chlamydia trachomatis 9 (9%) 3 (6%) 6 (11%)
Condylomata accuminata 5 (5%)  5 (9%)
Other 7 (7%) 7 (13%)
†Fisher’s Exact P< 0.01.
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to identify individual HPV types in case the PCR-EIA was posi-
tive.216 We used β-globin PCR to identify sampling errors and to 
monitor for PCR inhibitors. 
Statistical analysis
The risk of development of high-grade CIN associated with 
hrHPV presence was assessed with the Fisher exact test and Chi-
square. Confi dence intervals of 95 percent and 2-sided P-values 
were used. 
6.4. Results
A total of 105 women met the inclusion criteria. The mean age 
was 39 years (range 30-60 years). The median time-lag between 
the two BMD smears on the basis of which women were referred 
was 7 months, with a range of 2-20 months. The median time-
lag between the second BMD smear and colposcopic examination 
was 2 months (range 0-8 months). 
At baseline 54 women (51%) were hrHPV positive, leaving 
51 hrHPV negative subjects (Figure 6-1). HPV 16 and 31 were 
the most frequently detected hrHPV types (40% and 20% of all 
infections, respectively). Other types were less common: HPV 
18 (7%), HPV 33 (10%), HPV 35 (7%), HPV 42 (7%), HPV 45 
(2%), HPV 51 (7%), HPV 52 (10%), HPV 56 (10%), HPV 58 (7%), 
HPV 59 (2%) and HPV 66 (2%). Of the observed HPV positive 
scrapings at baseline, 68% contained single infections and in 
the remaining 32% a multiple infection was detected. With one 
exception, all hrHPV negative women demonstrated no or a low-
grade lesion at baseline biopsy: 27 women without dysplasia 
(53%) and 23 women with CIN 1 (45%). One hrHPV negative 
woman had a CIN 2 lesion at baseline. 
Among hrHPV positive women at baseline, 35 cases (65%) 
had ≤CIN 1 and 19 cases (35%) CIN 2-3. The fi rst group consisted 
of 10 women (19%) without dysplasia and 25 women (46%) with 
a CIN 1 lesion, whereas the high-grade CIN group comprised 14 
women (26%) with a CIN 2 lesion and fi ve women (9%) with a 
CIN 3 lesion. 
Table 6-1 shows the characteristics of the study population 
stratifi ed according to hrHPV presence at baseline. When age 
is stratifi ed in three categories 30-40, 40-50 and 50-60 years 
respectively, we see a signifi cant difference for the young-
est group (30-40 years) where hrHPV is more frequently pres-
ent (P<0.01). The presence of CIN 2-3 was signifi cantly higher 
in women who were hrHPV positive at baseline, compared to 
hrHPV negative women (P<0.01 with an odds ratio of 27 (95% 
CI: 3-211)). Women who were hrHPV negative were less likely to 
have a history of sexually transmitted disease (P<0.01). Other 
risk factors such as education, ethnic background, sexarche, 
number of sexual partners in the preceding year, smoking and 
oral contraceptive showed no difference of statistical signifi -
cance between groups with and without HPV infection. 
Follow-up of hrHPV negative women
One woman acquired hrHPV infection after 12 months, with-
out progression to high-grade CIN. All other women (50/51) 
remained hrHPV negative and did not develop a high-grade 
CIN lesion. The woman with a high-grade CIN lesion at baseline 
showed histological regression to no dysplasia after 12 months 
(Table 6-2). 
Follow-up of hrHPV positive women
Nineteen of the 35 hrHPV positive women (54%) with ≤CIN 1 at 
baseline demonstrated persistence of hrHPV infection after 12 
months. Five out of these 19 (26%) showed progression to high-
grade CIN. No (micro) invasion was detected. Fourteen women 
without hrHPV clearance continued to have ≤CIN 1. Clearance 
of hrHPV infection occurred in 16/35 women (46%), none of 
whom showed progression detected in histological biopsies, i.e. 
14 women without dysplasia and 2 women who still had CIN 1 
after 12 months. 
Among the 19 women with a high-grade lesion three (16%) 
cleared the hrHPV infection after six months, with histological 
regression to a low-grade lesion, and remained hrHPV negative 
after 12 months. Amongst the 16 women who were still hrHPV 
positive after 6 months (84%) 10 (63%) revealed a (persistent) 
high-grade lesion. No (micro) invasion was detected. These 10 
women were treated. The remaining six women (37%) demon-
strated regression to a low-grade lesion. One of them was treated 
at her own request and therefore left the study group prema-
turely. After 12 months two out of fi ve women remained per-
sistently hrHPV positive, one of whom had a high-grade lesion 
(CIN 2). The other three women showed clearance of hrHPV and 
a low-grade lesion on histology. 
6.5. Discussion
In this study progression to a high-grade CIN lesion was not seen 
in hrHPV negative women with a persistent BMD smear detected 
in the national screening program. All women with a high-grade 
lesion were hrHPV positive at baseline, except for one woman 
who had a CIN 2 lesion at baseline and was hrHPV negative. His-
tology from this patient showed regression to a low-grade lesion 
after 12 months, suggesting that for this woman clearance of 
hrHPV was already evident at baseline, with subsequent regres-
sion of the lesion becoming apparent after 12 months. This cor-
responds with the fi ndings of other studies.26, 106, 208 
In our study, the negative predictive value (NPV) of hrHPV 
testing for having high-grade CIN was 98% at baseline for women 
with a repeated BMD smear, and 100% after 6 and 12 months 
follow-up. This suggests that hrHPV negative women, despite a 
persistent BMD cytology, are not at risk for high-grade CIN. 
Various studies have shown that better results are obtained 
using HPV detection when compared with conventional cytology 
Table 6-2. Histology outcome related to HPV status at baseline.
Baseline t=6 months† t=12 months
≤CIN 1 CIN 2-3 Total n 
(%)
≤CIN 1 CIN 2-3 Total n 
(%)
≤CIN 1 CIN 2-3 Total n 
(%)
HPV-positive (n) 35 19 54 (51%) 9 10 19 (100%) 37 6 43 (41%)
HPV-negative (n) 50 1 51 (49%) - - - 51 0 51 (49%)
Total (n) 85 20 105 9 10 19 88 6 94‡
†Only HPV positive CIN 2-3 had t=6 months follow-up. ‡11 women treated (10%).
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(i.e. NPV cytology 93-98%).5, 101, 211 Triage with HPV-testing as 
an adjunct to cytology has been proposed for women with min-
imal cytological changes.208, 209, 213 Several studies have used 
different classifi cations of mildly abnormal cytology.106, 208, 211, 
213, 219-221 Cuzick et al. included women with borderline cytol-
ogy and negative cytology but hrHPV positive (HART study).213 
The ALTS study describes triage in women with ASCUS and LSIL 
cytology (ALTS Group).222 An overview of triage studies with 
corresponding data is shown in Table 6-3. Selection was based 
on HPV detection methods that were clinically validated in lon-
gitudinal studies (i.e. HCII and GP5+/6+ PCR), since the clinical 
rather than the analytical performance of HPV detection meth-
ods should be considered for triage policies.223 The main ben-
efi t that can be concluded from all listed studies is a reduction 
in referral of hrHPV negative women with minimal abnormal 
cytology for colposcopy. For more severe cytological abnormali-
ties the use of triage with HPV-testing is not indicated. Our 
study was based on women referred to the gynaecologist for two 
times BMD smear according to the national guidelines. Based 
on our results we suggest that women with a persistent BMD 
smear and a concomitant negative hrHPV test result are not 
at risk for development of cervical cancer and should stay in 
the screening program, without colposcopic evaluation. In the 
Netherlands the next scheduled screening would then take place 
after 4.5 years. The risk that a woman will develop high-grade 
CIN within that period of time seems acceptable, since it will 
be exceptional to take place within 5 years given that a per-
sistent hrHPV infection is required.37, 100 Precursor lesions are 
detectable within an average of 10-15 years before progression 
to cancer.34 Thus, even though our study only covers 12 months 
of follow-up, it seems reasonable to return women with a hrHPV 
negative persistent BMD smear into the screening program with-
out additional surveillance or treatment. However, an estimate 
of excess risk among hrHPV negative women with BMD cytology 
is expected within the next few years when e.g. the ongoing 
Dutch POBASCAM screening study and Swedish screening study 
are expected to yield fi nal results.15, 138
In our study 54/105 women (51%) were hrHPV positive at 
baseline of whom 19 (35%) had a histologically confi rmed high-
grade CIN lesion. The overall frequency of high-grade CIN was 
19%, which is comparable with the fi ndings of Ho et al.106 In 
contrast, a previous study by our group demonstrated a preva-
lence of 10%.109 In that study however, about half of the women 
were referred after one BMD smear in contrast to our current 
g
(1 panel) 
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Figure 6-2. Policy proposal, illustrated on a hypothetical number of 1,000 patients. Reduction of 67% referral for 
colposcopic evaluation (49 + 18), 9 percentage points or 9/24*100=38% less treatment (current directions 25/105 (24%) 
treated vs. proposed proposal 16/105 (15%) treated) accomplished if 151% HPV-testing is added.
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study where women were referred after two BMD smears in 6 
months. Consequently, this group with BMD contains more 
women with mild dyskaryosis than the previous group (38% vs. 
26%) (data not shown). Therefore, our results can be explained 
by the fact that the prevalence of high-grade CIN increases with 
severity of abnormal cytology.27, 211 
In this trial women with a high-grade lesion were not 
treated immediately. A ”wait-and-see” period of six months 
showed persistence of high-grade CIN only in women with per-
sistent hrHPV infection. No patient developed (micro) invasive 
carcinoma. These fi ndings suggest that a wait-and-see period 
for (at least) six months involves no additional health risks. In 
addition, 16% of these women showed clearance of hrHPV with 
a subsequent regression of the lesion. They were no longer at 
risk of development of high-grade CIN, and consequently, an 
expectative policy could result in a reduction of the need for 
treatment. 
The majority of hrHPV positive women with a repeat BMD 
smear have low-grade CIN lesions (in our study 35 out of 54 
(65%) at baseline). This is in agreement with the fi ndings of 
previous studies.41, 106, 208, 211, 213, 219-221 Approximately half of 
these women cleared hrHPV in 12 months and none of them 
developed a high-grade CIN during this time. Fourteen percent 
developed high-grade CIN after 12 months (all were persistently 
hrHPV positive), without an observed development of (micro) 
invasive carcinoma. It should, however, be considered that the 
biopsies taken to establish the severity of premalignant lesions 
may have interfered with the natural course of disease. On the 
other hand, several natural history studies have demonstrated 
that HPV clearance and histological regression occur after 6-12 
months.26, 204, 224 Our follow-up time of 12 months should there-
fore cover the major part of regression. Consequently, referral 
can therefore be restricted to women with a repeat BMD smear 
who remain persistently hrHPV positive for at least another 
six months.
Although our proposal requires more hrHPV testing (100%), 
according to the present study it will lead to a 49% reduction in 
referrals for colposcopy. A ‘wait-and-see’ period in the HPV posi-
tive group for at least six months will result in a supplement of 
51% HPV-testing and a further 18% reduction in referrals and 
9 percentage points treatment reduction. In summary, a total 
reduction of 67% referrals for colposcopic evaluation and 38% 
less treatment can be obtained by addition of 151% HPV-test-
ing. The 6 months wait-and-see period in hrHPV positive women 
may also have negative infl uences on the women involved. 
Some women might prefer a see-and-treat policy instead of a 
more conservative approach. Proper information and explana-
tion of the natural development of premalignant lesions in rela-
tion to hrHPV infection by the physician is therefore required, 
after which patients preference may infl uence further choices 
especially in this group.30 The potential gain of less treatment 
however, remains to be weighted against potential changes in 
quality-of-life and effectiveness. Our recommendations are sum-
marised in Figure 6-2. 
In conclusion, triage using hrHPV testing for women with 
a persistent borderline or mildly dyskaryotic cytology is rec-
ommended. Women can stay in the screening program without 
referral to the gynaecologist if no hrHPV infection can be deter-
mined. We suggest a repeat HPV test after another six months for 
hrHPV positive women. Referral for colposcopy is only required 
if persistence of hrHPV is demonstrated. Women who cleared 
hrHPV infection are no longer at risk of development of prema-
lignant lesion. Further surveillance can take place within the 
screening program at the protocollized interval of fi ve years. 
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7.1. Abstract
The conventional direct referral to colposcopy of persistent bor-
derline or mildly dyskaryotic (BMD) smears in cervical cancer 
screening leads to considerable unnecessary referrals and asso-
ciated anxiety and costs. This may be improved by including 
testing for oncogenic human papillomavirus (HPV) in the triage. 
We assessed costs and side effects (referrals, treatments, time 
in follow-up) for three possible HPV triage strategies (immedi-
ate HPV testing, a 6-month delay in HPV testing, a two-stage 
combination of both) and compared them with the conven-
tional strategy. The assessments are based on recent Dutch data 
from various national databases and trials. We estimated that 
the referral rate could be reduced by 49%, 58% and 58% with 
immediate, delayed and two-stage HPV testing, respectively. As 
a consequence, the average length of follow-up, as well as aver-
age costs, also decrease. Therefore we advocate including HPV 
testing before referring to colposcopy. Among the three HPV 
strategies, analysis of additional aspects favours implementa-
tion of immediate HPV testing. 
7.2. Background
Cytology-based cervical cancer screening prevents deaths by 
treating pre-invasive (cervical intraepithelial neoplasia - CIN) 
and early invasive disease. Low-grade abnormalities described 
as borderline and mild dyskaryosis (BMD) are the most com-
mon type of cytologic abnormalities, ranging in frequency from 
below 2% in the Netherlands to above 6% in Finland.Chapter 2 
In several countries, it is currently recommended to follow up 
these women with a Pap smear in 6 months.49, 102, 103 Women are 
then referred for a colposcopy if the BMD abnormality does not 
normalise.49 In the Netherlands, about one third of the women 
with BMD primary screening smears is eventually referred,Chapter 
2 most often because of BMD persistence and less often because 
of cytological progression.225
This diagnostic policy of following-up BMD smears induces a 
considerable amount of side effects in terms of a high number of 
referrals and a long follow-up period with associated costs and 
psychologic consequences. Sixty to ninety percent of women 
with BMD persistence have no high-grade lesion that needs 
to be treated.104-109, 226, Chapter 6 The burden on women and the 
health care could be reduced if the subgroup at high risk for a 
signifi cant lesion were identifi ed. 
It has been consistently shown in the literature that detec-
tion of an infection with one of the high-risk human papilloma-
virus types (HPV) can be used for a risk stratifi cation of women 
with low-grade abnormal smears.101, 208 An infection with HPV 
is a necessary factor in the development of invasive cervical 
cancer.5 Because no histological progression is seen in women 
who spontaneously clear the HPV infection,5 women without a 
detectable HPV infection do not need further follow-up. That 
could be the case in 40-60% of women with persistent BMD 
smears.104-109, Chapter 6 The discussion about the optimal strat-
egy and time points of incorporating HPV testing into triage of 
women with BMD smears is still on-going.227-229
To inform this discussion, we investigated the costs and the 
side effects of three strategies of managing women with persis-
tent (defi ned as two consecutive) BMD smears using HPV testing 
as a triage tool. Both the side effects and the costs are com-
pared to those associated with the conventional management 
(i.e., direct colposcopy of all women without fi rst assessing their 
HPV status).
7.3. Methods
Triage strategies
We analysed three possible HPV triage strategies of women with 
two consecutive BMD smears (Figure 7-1; corresponding to ASC-
US+ASC-H+LSIL in the Bethesda 2001 classifi cation40). The dif-
ference among these strategies is in the timing of HPV testing, 
and the consequent referral to colposcopy: 
− A – immediate HPV triage: the co-collected HPV sample is 
analysed immediately when BMD persistence is established 
(t=0), and all HPV-positive women are referred to colpos-
copy; 
− B – delayed HPV triage: an HPV sample is collected six 
months after the second BMD smear (t=6), and all HPV pos-
itive women (i.e., those who have not cleared the virus) are 
referred to colposcopy; 
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− C – two-stage HPV triage: the co-collected HPV sample is 
analysed immediately when BMD persistence is established 
(t=0), HPV-positive women are re-tested for HPV at t=6, 
and all women who remain HPV-positive (i.e., those who 
have not cleared the virus) are referred to colposcopy. 
We assumed that in strategies A and C the HPV samples are co-
collected when the woman presents at the general practitioner 
(GP) to have a follow-up Pap smear after a BMD primary screen-
ing smear (both conventional cytology). These HPV samples are 
investigated if the follow-up smear is read as BMD. Women with 
one negative HPV test return to a normal screening schedule. 
The three HPV strategies were compared for side effects and 
costs to: 
− D – conventional strategy: direct colposcopy, i.e. a refer-
ral at t=0 of all women with two consecutive BMD smears 
without a prior assessment of their HPV status. 
Quantifi cation of side effects and costs
We assessed the side effects and costs per woman with two con-
secutive BMD smears for the period after the second BMD smear. 
This period includes all HPV sampling for triage and the com-
plete post-referral management. 
In the Dutch cervical cancer screening programme, roughly 
1 in 4 women with a primary BMD smear has a follow-up (=sec-
ond) BMD smear; the remaining 3 in 4 women have either a neg-
ative follow-up smear, or a highly abnormal (>BMD) smear.225 
Because of co-collection at t=0 in strategies A and C, when the 
outcomes of cytologic testing are not yet known, HPV samples 
would need to be taken from all women with a primary BMD 
smear. This represents extra costs compared to the conventional 
strategy, and needs to be taken into account in the analysis. 
Therefore, in these two strategies we assumed that three extra 
HPV samples need to be collected for each woman with two 
consecutive BMD smears. We further assumed that only those 
collected samples that are relevant for our analysis, i.e. 1 in 4, 
are read in the laboratory. 
The proportion of women referred, the proportion treated 
and the time needed to complete the recommended follow-up 
are quantifi ed from epidemiological data from a recent Dutch 
trial performed at the Erasmus Medical Center (Erasmus MC) 
reported earlier.Chapter 6 This trial aimed to evaluate the potential 
to prevent unnecessary diagnostic procedures and treatments 
by doing the HPV triage of women with two consecutive BMD 
smears corresponding to strategy C. At enrolment, the gynaecol-
ogist took an HPV sample and biopsies from all colposcopic 
abnormalities but treatment was deferred. Women with an HPV-
positive high-grade (CIN 2/3) lesion at enrolment were followed-
up 6 months later with an HPV test and a colposcopically guided 
biopsy. If the HPV-positive CIN 2/3 lesion persisted, the woman 
was treated. If instead within 6 months the woman cleared the 
virus or no CIN 2/3 lesion could be established anymore, she was 
seen at the exit visit 12 months after enrolment together with 
those women who tested HPV-negative at enrolment or had (at 
most) a low-grade lesion (CIN 0/1). At this exit visit, women 
were tested for HPV and underwent colposcopy. At enrolment, 
51% of women had detectable HPV (Table 7-1). Nineteen percent 
of all enrolled women were found to have a CIN 2/3 lesion at 
t=0, i.e. 35% of all HPV-positive and 2% of HPV-negative women. 
The observed 12-month progression and persistence proportions 
of (untreated) CIN 0/1 lesions (CIN 0 to >CIN 0, and CIN 1 to 
≥CIN 1; both transitions may prompt treatment during post-col-
poscopic follow-up) were dependent on the HPV status at enrol-
ment (Table 7-2). No cancer was found during follow-up. 
In the Erasmus MC trial, the HPV status and the distribution 
of CIN lesions at t=6 were not directly observed for all women. 
We applied a multi-state Markov model on the longitudinal data 
of all HPV-positive women at enrolment (n=54), using the HPV 
and CIN prevalence observed at t=0 (for all 54 women), at t=6 
(for the subgroup with HPV-positive 
CIN 2/3 at enrolment), and at t=12 
(for women with HPV-positive CIN 0/1 
at enrolment, and women without per-
sistent HPV-positive CIN 2/3 at t=6). 
The result of this model was an esti-
mate of HPV and CIN prevalence for all 
54 women at t=6. We used the msm 
package for the statistical program R 
version 0.6.3 (Christopher Jackson, 
Department of Epidemiology and Public 
Health, Imperial College, London). We 
allowed for the following transitions: 
HPV clearance, CIN progression and CIN 
regression, and assumed that women 
treated at t=6 would without treatment 
have remained in the same state until 
t=12. This lead to an estimate that 18% 
of HPV-positive women at t=0 cleared 
this infection by t=6 (Table 7-1). With 
the same model we also estimated that 
44% of women who do not clear the 
HPV by t=6 have CIN 2/3. 
For the HPV prevalence and per-
sistence rates and the CIN 2/3 preva-
lence, we extracted the plausible ranges 
Strategy D 
 
Strategy C 
 Strategy B 
 
Strategy A 
 
 
 
 
Figure 7-1. Strategies A, B, C, and D (conventional strategy) for triage of persistent 
BMD smears. Shaded rectangles represent women who need to be referred, whereas 
the rectangles with a bold border represent women who can return to the regular 
screening programme.
Strategy A
Strategy B
Strategy C
tegy D
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from the literature104-109, 226 and used them as the 
basis for univariate sensitivity analyses. In all 
cases where independent observations were avail-
able, these formed an interval around the point 
estimates observed in the Erasmus MC trial (Table 
7-1). 
We defi ned the average duration of follow-
up as the period following the second BMD smear 
in which women are further triaged through the 
HPV test (strategies A, B and C), referred and fol-
lowed-up. We assumed compliance with the rec-
ommended follow-up (surveillance) after colpos-
copy. In the Netherlands, women with CIN 0/1 
at initial referral are not treated but it is recom-
mended to follow them up with 2 smears within 
12 months; women with CIN 2/3 at initial referral 
are offered treatment and are then followed-up 
with 3 surveillance smears within 24 months.230 
If in either case at least one surveillance smear is 
abnormal, the woman is referred for colposcopy 
again and eventually (re-)treated. We accounted 
for the extra follow-up time due to surveillance 
based on the progression/persistence rates of 
CIN 0/1 observed in the Erasmus MC trial, and on 
post-treatment residual/recurrence rates for CIN 
2/3 extracted from the literature (Table 7-2). In 
this way, we neglected the extra follow-up time 
because of negative colposcopies in women with 
(false-)positive surveillance smears. We assumed 
that the abnormal surveillance smear is found 
at the mid-point of the recommended follow-up 
interval. The assumed time needed between the 
successive management steps is then as follows: 
2 months from the positive triage test to colpos-
copy, 1 month from colposcopy to treatment, 6 
months for post-colposcopy surveillance of CIN 
0/1, and 12 months for post-treatment surveil-
lance of CIN 2/3. 
We estimated that from the moment the refer-
ral advice is given it takes on average 10, 14, and 
17 months to complete follow-up for CIN 0, CIN 1, 
and CIN 2/3, respectively. These estimates, used 
for the evaluation of the conventional strategy 
D, are based on the combination of the observed 
persistence/progression proportions (Table 7-2), 
and the recommended length of post-referral fol-
low-up, both per CIN stage and regardless of the 
HPV status. In strategies A, B and C all referred 
women are HPV-positive. Untreated HPV-positive 
CIN 0/1 lesions are more likely to be referred 
once again due to higher persistence/progression 
proportions of the lesion than the HPV-negative 
CIN 0/1 lesions (Table 7-2). In these strategies, 
therefore, the estimated average follow-up time 
per CIN stage increases to 13 and 15 months for 
CIN 0 and CIN 1 lesions, respectively. 
Direct medical costs, and the time and travel 
cost incurred by women were included in the 
analysis. The costs per procedure, and the average 
number of diagnostic and treatment procedures Ta
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during post-referral management (diagnostics, treatment and 
follow-up) per CIN grade regardless of the HPV status, repre-
sent the recent Dutch situation69, 231 (Tables 7-3 and 7-4). The 
average number of procedures per CIN stage69 are based on the 
assumptions that (a) the given CIN grade is the maximum CIN 
grade, and that therefore women with CIN 0 are never treated, 
(b) 44% of women whose CIN 1 lesion is expected to persist 
or progress37 are subsequently treated, (c) all women with CIN 
2/3 are treated immediately, and (d) 10% of the women treated 
will need retreatment.232 These assumptions and the estimated 
treatment modalities published earlier41, 231 were validated 
against the most recent available individualised national data 
on diagnoses, diagnostic procedures and treatments.128, 225 For 
the purpose of the present cost analysis, we also accounted for 
progression of CIN 0, and at least persistence of CIN 1 lesions by 
HPV status (see Table 7-2). We assumed that all women showing 
progression (or persistence of CIN 1) are treated.
7.4. Results
While all women undergo a colposcopy under the conventional 
strategy (strategy D), only 51%, 42% and 42% would have been 
triaged to it by HPV under strategies A, B, and C, respectively 
(Table 7-5). The expected total detection rate of women with 
high-grade CIN lesions (CIN 2/3) would be 18%, 
18%, 18% and 19% of the eligible women under 
strategies A, B, C, and D, respectively. The avoided 
referrals would therefore predominantly concern 
women with at most low-grade CIN lesions (CIN 
0/1). While 81% of all women with two consecu-
tive BMD smears turned out to have CIN 0/1 at 
referral in the trial (strategy D), this would only 
be 33%, 23% and 23% under strategies A, B, and 
C, respectively. As a consequence, the total treat-
ment proportion would amount to 32%, 28%, 28% 
and 41% under strategies A, B, C, and D, respec-
tively. This proportion includes immediate treat-
ment of women with CIN 2/3 lesions at referral, 
and later treatment of initially untreated women 
(CIN 0/1 at referral) who show abnormalities in 
follow-up. 
We estimated that the total follow-up after 
the second BMD smear takes 13 months on aver-
age under the conventional strategy D (Table 7-5). 
This period predominantly refl ects the time needed to complete 
the recommended management after referral. Therefore, the 
average length of follow-up per strategy is strongly affected by 
the lower referral rates in the HPV strategies. These outweigh 
the prolongation of the pre-referral period due to the extra HPV 
triage, so that in the end the completion of follow-up after the 
second BMD smear would on average take 8, 12, and 10 months 
under strategies A, B, and C, respectively. The expected average 
difference between strategies A and C is small though it should 
be noted that the subgroup that is referred based on delayed 
HPV testing (strategy C) is at a disadvantage. This is because 
they spend extra time in triage while the fact that they are 
referred and their post-referral management do not change. 
We estimated that the total cost to manage a woman with 
two consecutive BMD smears under the conventional strategy 
(D) is €740 (Table 7-5). HPV testing itself would add to the tri-
age costs, but these extra costs would be lower than the savings 
due to fewer referrals. The resulting difference is most favour-
able for strategy B (a decrease of 36% compared to strategy D), 
followed by strategies C (35%) and A (30%). 
In the sensitivity analysis, we varied the epidemiologic 
assumptions with ranges from the literature reported in Table 
7-1. In Table 7-6, we present the effects on the referral rate, 
the average length of follow-up and total costs. The ranking 
of strategies does not change. All three HPV strategies would 
remain more favourable than the conventional strategy. Under 
all investigated possibilities except when a lower HPV persis-
tence rate is assumed (60% instead of 82%), strategy A would 
remain the most favourable in terms of the time needed to com-
plete the total recommended follow-up. When the lower HPV 
persistence rate is assumed, strategy C could decrease the aver-
age time in follow-up to the same level as strategy A. The pro-
portion of women referred and treated, as well as the total cost, 
would remain the lowest under strategies B and C: the referral 
rate in the range of 31-49%, and the cost decrease compared to 
strategy D in the range of 33-51%. Our results are most affected 
by the changes in the assumptions on HPV prevalence and its 
persistence within 6 months (direct observations for the latter 
are not available). This is not surprising since these determine 
how many women will be ultimately referred for colposcopy. 
Table 7-2. Proportion of women with persistence or 
progression of the initial lesion, as observed during 12 
months in the Erasmus MC trial. 
Initial CIN 0 lesion to >CIN 0† 14%
HPV-negative at enrolment 7%
HPV-positive at enrolment‡ 30%
Initial CIN 1 lesion to ≥CIN 1† 38%
HPV-negative at enrolment 26%
HPV-positive at enrolment‡ 48%
Post-treatment recurrent or 
residual lesions in CIN 2/3 ∫
10%232
†Determined by pooling the trial outcomes for HPV-positive 
and HPV-negative women. Used for evaluation of strategy 
D. ‡Used for evaluation of strategies A, B and C. ∫Used for 
evaluation of all four strategies.
Table 7-3. Average number of diagnostic and treatment procedures 
per CIN grade regardless of HPV status, based on national data for the 
Netherlands.69 
Histology
CIN 0 CIN 1 CIN 2 CIN 3
Diagnostic procedures:
Colposcopy 2.11 4.45 4.77 5.05
Smear by a 
gynaecologist
1.61 2.59 3.10 3.13
Biopsy 0.37 0.63 0.65 0.62
Endocervical curretage 0.13 0.37 0.35 0.38
Smear by a GP 0.40 0.51 0.44 0.32
Treatment procedures:
LETZ† 0.13 0.42 0.93 0.75
Conization 0.01 0.04 0.15 0.30
Hysterectomy 0.00 0.02 0.02 0.04
†Loop excision of the transformation zone.
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7.5. Discussion
Our analyses showed that compared to direct referral of women 
with two consecutive BMD smears to colposcopy a referral based 
on HPV testing can prevent at least one out of two colposcopies 
and treatment in one of three women with at most low-grade 
lesions. It can decrease the average follow-up time by half a 
year, and reduce the associated average total costs by a third. 
In the population of 3.4 million women at risk (i.e., with a 
cervix) aged 30-60 in the Netherlands, around 8,700 annually 
have a BMD primary screening programme smear in the screen-
ing programme, of whom around 2,200 are referred due to BMD 
persistence.225 Even if strategy A with the lowest expected cost 
decrease would be adopted instead of the currently recom-
mended direct colposcopy (strategy D), total annual savings of 
close to €0.5 million could be attainable in this group of women 
in the Netherlands. BMD primary smears outside of the screen-
ing programme account for roughly half of the BMD primary 
smears in the Netherlands,225 so savings could double if the rec-
ommendation for HPV triage would extend from smears within 
the screening programme to all smears. Savings per screened 
woman could be higher in areas where the proportion of BMD 
primary smears is higher (e.g. >5% in Finland and England com-
pared to <2% in the Netherlands).Chapter 2 
None of the three analysed HPV strategies is optimal for 
both side effects and costs. Delaying the HPV testing by 6 
months (strategy B) may have the lowest total costs (Δ=-36% 
compared to direct colposcopy in strategy D) but for the com-
bination strategy C the costs are only slightly higher. The risk 
selection is equally good for strategies B and C (both strategies 
establish HPV persistence before a referral), but the period of 
time in which women are kept in triage is on average 3 months 
shorter for strategy C. Strategy A eliminates the need for an 
extra triage period and extra GP visits, but it is less powerful in 
selecting women at higher risk for progression to cancer than 
strategies B and C. 
The rationale for screening programmes is early detection 
and treatment of disease. In our analyses, we assumed equal 
effectiveness of each triage strategy, i.e. that there are not more 
cervical cancer deaths in the HPV strategies than in the direct 
colposcopy. This assumption can be challenged for two reasons. 
First, in the HPV strategies only women with detectable HPV 
infections, i.e. women at risk for cancer, are referred for col-
poscopy. A recent meta-analysis estimated that 95.5% of all CIN 
2+ lesions can be identifi ed if women with primary ASCUS and 
LSIL smears (which approximately correspond to BMD smears) 
are tested for HPV.233 Because at the time of histologic testing 
some women may have already cleared the HPV without yet hav-
ing their lesion regress, or might still clear the HPV later, only 
(an unknown) part of the remaining 4.5% may represent poten-
tial loss of sensitivity in detecting CIN 2+ compared to direct 
colposcopy (strategy D). On the other hand, recent data from 
the ALTS trial suggests that HPV testing may perform no worse 
than, or may even outperform colposcopy in identifying high-
grade CIN lesions.234 Follow-up data from the currently on-going 
randomised trials, e.g. that from the POBASCAM study expected 
shortly,15 will shed more light on the loss of sensitivity of HPV 
triage due to less frequent referral. Second, in the Netherlands 
the conventional guidelines of following up the BMD primary 
smear by a follow-up smear in 6 months implicitly accept the 
risk of postponing treatment to occult underlying cancers in 0.4 
per 1,000 women with BMD primary screening smears.225 When 
HPV testing is delayed for another 6 months (i.e., to 12 months 
after the BMD primary smear), the risk of diagnosing an inva-
sive cancer is a further 0.9 case per 1,000 women with a BMD 
primary screening smear.225 Should strategies B or C be adopted, 
postponing referral would miss another six months of lead-time 
for treatment in these 0.9/1,000 women. Given that these are 
screen-detected cancers, one may assume that despite this delay 
it is likely that they are still found at an early enough stage of 
invasion to retain the good 5-year prognosis of 90% survival.235 
To sum up, we can reasonably assume that the effectiveness of 
the three analysed HPV triage strategies and of the conventional 
strategy are comparable. 
An alternative to the analysed triage strategies could be 
to drop the requirement of fi rst establishing the persistence 
of the BMD smear and to instead triage solely through HPV, 
that is directly after one primary BMD smear. Per 1,000 women 
with primary BMD smears, such an approach would expectedly 
increase the referral rate by 100, the CIN 2/3 detection rate 
by 10-15, and prevent 1-3.5 cancers (Appendix, Chapter 7.6.). 
Given the very long (>10years) average duration of preinvasive 
lesions,34 some of these 1-3.5 per 1,000 women will still have the 
chance to be managed early at the next screening round in less 
than 5 years. This balance is not straightforward, and remains 
uncertain. Again, the expected long-term follow-up data from 
Table 7-4. Unit costs (€ 2005) of medical procedures, visits 
and hospital stays, based on the recent Dutch data.69, 231
Procedure Unit cost
Pap smear, taken by a GP† 45
Pap smear, taken by a gynaecologist‡ 25
Co-collected HPV test 1
HPV test at an extra GP appointment∫ 59
First colposcopy 86
Second or later colposcopy 63
Biopsy 50
Endocervical curettage 81
LETZ§ 490
Conization§ 1,195
Hysterectomy§ 4,176
Average total cost (referral + post-referral management): 
- CIN 0 336 (420 if HPV-positive)
- CIN 1 828 (884 if HPV-positive)
- CIN 2 1,239
- CIN 3 1,432
†Includes the visit at the GP and the collection of sample 
material (€21), laboratory cost (€17) and costs of the woman 
(€6). ‡The laboratory cost. Collection of sample material and 
costs of the woman are included in the cost of colposcopy. 
∫Includes visit at the GP and collection of sample material 
(€21), laboratory costs (€33), and costs of the woman (€6). 
§Treatment costs include the charge per type of treatment 
(LETZ €294, conization €477, hysterectomy €1,062), cost 
of outpatient visit (if the procedure is performed in an 
outpatient setting; €64), cost of hospital days (day care €229, 
hospital day €359), preoperative diagnostics (for conization 
or hysterectomy €98) and costs for the woman (€9 for an 
outpatient visit, and €42 per treatment day). 
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randomised trials such as the POBASCAM study should in the 
near future help improve these estimates. Also, adding further 
markers to HPV-testing (e.g. typing for HPV 16 and 18, testing 
for mRNA) is currently under investigation as feasible ways to 
improve specifi city, which would more likely favour HPV-testing 
above cytological triage. 
This study has some limitations. First, some women who 
in the Erasmus MC trial had a persistent HPV-positive CIN 2/3 
lesion from t=0 to t=6 (this prompted treatment and censoring 
from further follow-up) could have cleared the HPV by t=12. 
Therefore the assumption we used to fi t our interpolation model 
with – that women treated at t=6 would have remained in the 
same state until t=12 had they not been treated – may give an 
overestimate of HPV and CIN 2/3 persistence, and an overesti-
mate of the referral rate and costs for strategies B and C. On the 
other hand, the quantifi cation of strategies B and C is based on 
the data from a trial in which biopsies were taken at enrolment 
from all colposcopic abnormalities. Biopsies may have interfered 
with the development of the disease, e.g. by removing HPV-
infected lesions which would not have cleared and/or regressed 
if left unbiopsied in the observed period. Consequently, the 
estimated 6-month HPV persistence rate may be too low, the CIN 
2/3 prevalence rate at t=6 too low, and the expected decrease 
in the referral and total costs too high. Though especially strat-
egy C seems interesting for implementation, we are less certain 
exactly how well it would in reality perform relative to strategy 
A. Given our assumptions, strategy C could avoid a referral to 
colposcopy in at most 9% more women than strategy A. The 
cost for this advantage is an extra GP visit and a 6-month longer 
triage period for 51% of women in strategy C. In the base-case 
calculation the extra GP visits in strategy C save 0.18 referrals 
and 0.07 treatments compared to strategy A. Strategy C would 
be preferred over strategy A only when it could be shown that 
the perceived burden of an extra GP visit and 6-month waiting 
time during triage will be less than 18% of that associated with 
a referral for colposcopy, and also less than 7% of that of treat-
ment. The relative burden is thus far unknown but it could be 
studied in an implementation trial in which the 6-month natu-
ral history of HPV could be monitored for this group of women 
without early biopsy interference. 
Second, because we wanted to study the optimal strategy 
to offer to women, we assumed compliance with follow-up in 
Table 7-5. Results: Number of procedures, side effects, and costs (€ 2005) due to HPV triage, diagnostic assessment and 
treatment per strategy, and per woman with two consecutive BMD smears. Base case assumptions.
Triage strategy
A 
(Immediate triage)
B 
(Delayed triage)
C 
(Two-stage triage)
D
(Direct colposcopy)
Number of procedures, side effects
HPV tests – co-collected 
samples† 4.00 0.00 4.00 n.a.
HPV tests – samples collected at 
extra GP visits‡ 0.00 1.00 0.51 n.a.
Proportion of women referred∫ 51% 42% 42% 100%
Detection of CIN 0§ 10% 7% 7% 36%
Detection of CIN 1§ 24% 17% 17% 45%
Detection of CIN 2§ 13% 14% 14% 14%
Detection of CIN 3§ 4% 5% 5% 5%
Proportion of women treated∞ 32% 28% 28% 41%
Average time in follow-up 
(months)¶ 7.7 12.4 9.5 12.9
Costs
HPV tests 37 59 67 n.a.
Referrals to colposcopy 478 412 412 740
Total 515 472 479 740
HPV tests (extra GP visits)
Per avoided referral 0.0 1.7 0.9 n.a.
Per avoided treatment 0.0 7.8 4.0 n.a.
t=0: immediately after the second BMD smear. t=6: six months after the second BMD smear. n.a.=not applicable. †E.g. for strategy 
C: It is observed in the Netherlands that 25% of all BMD primary smears have a repeat BMD smear.225 This means that for every 
woman with the second BMD smear, 4 co-collected HPV samples need to be taken in total. ‡E.g. for strategy C: 51% of women with 
two BMD smears are HPV-positive at t=0, and are retested for HPV at t=6. ∫E.g. for strategy C: 51% × 82% HPV persistence rate 
(Table 7-1). §Directly observed in the Erasmus MC trial for strategies A and D (see Table 7-1), and estimated for strategies B and C. 
∞E.g. for strategy C: women with HPV-positive CIN 2/3 (18%, see Table 7-5) + persistence or progression in women with initial CIN 
0/1 lesions (7% × 30% + 17% × 48%, see Tables 7-2 and 7-5). ¶E.g. for strategy C: 51% HPV-positive at t=0 × 6 months in triage + 
post-triage follow-up (7% × 13 months for CIN 0 + 17% × 15 months for CIN 1 + (14% + 5%) × 17 months for CIN 2/3, see Table 7-5 
& Methods).
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all strategies during the triage period. Lack of follow-up will 
decrease screening effectiveness. It has been shown in the lit-
erature that up to one third of the women do not comply with 
follow-up,236 and that the compliance decreases with longer time 
lags in recommended follow-up.237 Since women in our study 
have already had to wait for 6 months for the follow-up smear, 
these fi ndings are especially challenging for those strategies that 
involve extra prolonged periods of triage in which HPV is allowed 
to clear (strategies B and C). In the Netherlands, cervical cancer 
screening is performed at the primary health care level by gen-
eral practitioners (GP). A large audit of GP practices in the Neth-
erlands has shown that complex decision trees are important 
barriers to compliance of the GP with diagnostic guidelines.143 
All three HPV strategies increase the diagnostic complexity for 
the GP as they add to the currently routine practice a test of a 
different type, strategies B and C also at extra time points. 
Third, women’s preferences should play a role in optimis-
ing the triage strategies. In principle, triage through HPV could 
decrease anxiety in women with abnormal smears by decreasing 
the number of false-positive (i.e., HPV-negative) referrals. Still, 
follow-up of a large UK screening cohort showed that a negative 
HPV result does not signifi cantly reassure women with a BMD 
smear.238 Moreover, women who received a positive HPV report 
showed even higher anxiety levels after an abnormal smear.239 
Several surveys have shown that a signifi cant proportion of 
women with cytologic abnormalities may prefer an early referral 
to wait-and-see approaches,240, 241 and that a higher level of psy-
chological distress in a woman is an important factor contribut-
ing to such a choice.242 It seems then that it is especially the 
postponement of action in women who know that they tested 
HPV-positive in strategy C that could negatively affect their 
well-being, making strategy A more appealing to implement. 
In conclusion, our analysis provides further evidence that 
HPV can improve the specifi city of referral for colposcopy of 
women with persistent BMD smears, and decrease the burden on 
both the women and the health-care system. Given the estab-
lished high sensitivity of HPV testing for progressive cervical 
neoplasia, we therefore advocate including HPV testing before 
referring women. For these women, who are already in follow-
up for 6 months, analysis of additional aspects favours imple-
mentation of immediate HPV testing without waiting another 6 
months for clearance. 
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7.6. Appendix: Expected referral and 
detection rates for HPV triage, with and 
without cytology in triage
Assume strategies A1, B1 and C1 such that relative to the pri-
mary BMD smear (found at t=-6) the timing of HPV testing 
remains equal as in strategies A, B and C but the cytologic tri-
age (at t=0) is not done. As a consequence, HPV testing is done 
on all women with a BMD primary smear in strategies A1, B1 and 
C1, whereas it is only done on women with two consecutive BMD 
smears in strategies A, B and C. Ta
bl
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The expected referral rates, expressed as the proportion of 
all women with a BMD primary smear, are:
− Strategy A: 18% (25% with BMD in follow-up225 × 51% 
HPV-positiveChapter 6 + 5% with >BMD in follow-up;225 Figure 
7-A1);
− Strategies B and C: 15% (25%225 × 51%Chapter 6 × 77% (Table 
7-1) + 5%225);
− Strategy A1: 28% (35% of the women with a BMD primary 
smear are HPV positive15 × 81% HPV persistence rate in 6 
months;243 Figure 7-A1); and
− Strategies B1 and C1: 24-28% (35%15 × [68% (18 months)243 
to 81% (6 months) HPV persistence rate243]). 
The expected increase in the detection rate of CIN 2/3 
lesions in strategies A1, B1 and C1 over those of strategies A, B 
and C is 13.5 per 1,000 women with a BMD primary smear ((95% 
- 80%) difference in sensitivity for CIN 2+ of HPV vs. cytology 
triage233 × 9% prevalence of CIN 2/3 lesions in BMD primary 
smears109 × 1,000). 
It has been estimated that 10-24% CIN 2/3 lesions eventu-
ally progress to cancer.32, 37 Therefore, substituting the combi-
nation of a follow-up smear and an HPV test for a stand-alone 
HPV test in women with BMD primary smears could prevent at 
most 1.4 to 3.2 ([10% to 24%] × 13.5) invasive cancers.
Strategy A 
 
Strategy A1 
 
Figure 7-A1. Calculation of expected referral rate in strategies A and A1, after a single BMD primary smear. Shaded 
rectangles represent women who need to be referred, whereas the rectangles with a bold border represent women for whom 
we assumed that they return to the regular screening programme.
rategy A Strat  A1
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In this thesis, we studied the recent developments in the Dutch 
cervical cancer screening programme. In the Netherlands, cervi-
cal cancer incidence and mortality have been decreasing.4, 23, 24 
At present, cervical cancer is not anymore a common cause of 
death.4 Even though mortality already decreased before screen-
ing became widespread, the continuing decrease in the past 
three decades was also due to the screening programme: it was 
estimated that with a 75% coverage, the risk of dying from cer-
vical cancer would decrease by 50%.163 Women in a wide age 
range 30 to 60 years are invited every 5 years to have a Pap 
smear taken within the screening programme for which at pres-
ent about €30 million are spent yearly.60 
In this thesis, we showed that after the changes in the pro-
gramme’s organizational and fi nancial protocols and in medi-
cal guidelines since 1996, the extent of screening-induced side-
effects decreased considerably without negatively infl uencing 
the programme’s potential to prevent cervical cancer mortal-
ity. The estimated cost per life-year gained through screening, 
€9,000 (3% discounting of costs and effects), is acceptable.69 
Further, our research on HPV testing showed that the screening 
interval could be safely prolonged to more than 5 years if HPV 
test would replace the Pap smear, and that adding the HPV test 
to the triage of women with persistent low-grade cytological 
abnormalities can considerably decrease the present costs and 
side effects of follow-up. 
8.1. Answers to research questions
In this chapter, we will formulate and discuss the answers to the 
research questions that we wanted to address. 
1. What were the short-term effects of changes in 
the screening programme protocols and guidelines 
since 1996?
The screening coverage in the target age group increased, pri-
marily due to the substantial increase in the added age groups 
(30-34, and 55-64 years). The proportion of women with a non-
negative smear decreased by 80%, more women were compliant 
with the follow-up advice, and follow-up was completed faster. The 
total number of smears dropped by 20%, principally due to fewer 
follow-up smears. Overall, the changes in the programme since 
1996 led to an increase in the screening coverage, and a decrease 
in the screening-induced negative side effects.
Chapter 2 of this thesis took two snapshots of the screening 
programme, one in 1994 and another in 2003. In the meantime, 
more recent data (until 31st March 2007) became available. This 
data shows that, fi rst, improvements in the process indicators 
(the participation rates and the screening coverage, the pro-
portion of women with positive results, the compliance with 
follow-up recommendations, the number of smears made) were 
seen within 3 to 5 years after the implementation of the new 
protocols and guidelines, and second, that most process indica-
tors stabilized thereafter (Appendix, Chapter 8.6.). 
Since 1996, the coverage increased substantially,Chapter 2 but 
even with these high coverage rates, the majority of women 
diagnosed with cervical cancer were not screened, or were not 
screened regularly.72 This stresses the importance of further 
increasing the coverage. Several recent and on-going trials in 
the Netherlands are exploring new instruments to increase the 
coverage rate, e.g. self-sampling for HPV.131, 244 While the cover-
age rates have improved predominantly for older women (55-64 
years), no improvement has been observed since 1998 among 
women aged 30-34 years. For these women, the coverage rates 
are still lagging behind those of older women by about 10 per-
centage points. One of the tentative explanations for the rela-
tively low coverage rate is that around 13-14% of women aged 
30-34 were pregnant at any point in time in the period 2000-
2006.245 Pregnancy is a reason for delaying the smear (since 
2006 not also during the lactation period).57, 58 A more targeted 
scheduling of screening reminders for women who notify the 
screening organisation or their GP that they are pregnant could 
be one of the coverage-increasing options. 
The 1996 change discouraging screening before the age of 
30 gives new insights into whether the starting age under 30 
years would be benefi cial. Before 1996, more than one-quarter 
of women aged 20-29 had at least one smear in the preceding 5 
years, whereas by 2001 the coverage rate dropped to less than 
10%. Despite this, the incidence and mortality in age groups 
<30 and 30-34 did not increase.246 Within 20 years a decrease 
should be observable in these age groups if in the coming years 
a considerable proportion of 12-year old girls will be vaccinated 
for HPV. 
A lower cytologic threshold for referral to colposcopy of 
women with primary low-grade abnormal smearsChapter 2 raised 
the fear that the demand for colposcopy would increase sub-
stantially. This was not the case (Table 8-1). Immediately after 
the introduction of the new guidelines, the referral rate indeed 
doubled. This can be explained by a combination of several fac-
tors: an increased number of (primary) smears in the fi rst two 
years, an immediately increased proportion of primary smears 
with an immediate referral advice, and in the fi rst 2 years a 
still high proportion of smears with low-grade abnormalities 
(Appendix, Chapter 8.6.). In the years that followed, however, 
the demand for colposcopy decreased and remained at the level 
similar to that before 1996. 
2. Did the sensitivity of the Pap smear decrease 
after a broader defi nition of a negative smear?
No. The incidence of cervical cancer after a negative smear 
remained the same as it was before 1996, suggesting that the 
reduced smear positivity rate did not lead to a measurable 
decrease in smear sensitivity. 
Interval cancers arise either because of fast-growing lesions, 
or because the preceding screening rounds missed the lesion. 
In the recent period, approximately one quarter of cancer cases 
per year were preceded by normal smears,93 i.e. could be seen as 
interval cancers. These are the cancers that could theoretically 
be prevented by a more sensitive screening test, e.g. an HPV 
test. However, the proportion of cases preceded by a negative 
screening test depends on the screening coverage. For example, 
in a hypothetical situation with 100% coverage, all cancers after 
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the fi rst screening round would be interval cancers. It can there-
fore be expected that it if the coverage will continue to increase, 
the proportion of interval cancers will also increase. 
For effective screening, the management of positive screen-
ing results needs to be successful, as well. This is pursued by 
cytological follow-up, or by CIN treatment and post-treatment 
cytology. Negative follow-up (2 consecutive negative smears 
after a BMD smear, and 3 consecutive negative smears after CIN 
treatment) is seen as suffi cient evidence of absence of clinically 
relevant lesions. Like women with negative screening results, 
women with negative follow-up are assumed to be at low risk for 
cervical cancer and are recommended to continue participating 
in regular screening. This assumption remains to be empirically 
tested, both for BMD smears as well as for CIN lesions. 
3. Can screening be ceased for women with several 
negative smears by age 50? 
The risk for cervical cancer after the third consecutive negative 
smear around age 50 is comparable to the risk in younger women 
with similar screening histories. This does not speak in favour of 
making the screening policy less intensive for these older women 
but not similar younger women.
If surrogate endpoints are improperly used, they may lead 
to wrong conclusions.247 Also in our study, the CIN detection 
among well-screened women around age 50 was much lower 
than in younger women. In this respect, it corroborated the 
results of other studies. There is, however, strong evidence that 
the progression of CIN to cancer increases with age,34 and our 
study showed that the conclusions based on cervical cancer, 
the true clinical endpoint, differ from those obtained from CIN. 
Therefore, this analysis is an example of where CIN as a surro-
gate endpoint leads to the wrong conclusion, and underscores 
that its use should be carefully evaluated. 
The 1993 ex-ante cost-effectiveness analysis concluded that 
for the Netherlands the most effi cient cervical cancer screening 
policies would end only around age 70, almost irrespective of 
the screening interval (range: 5-10 years).55 Unless a new HPV 
vaccine will be developed which will be effective in women who 
were previously infected with HPV, screening will for at least 
four decades remain the only available option for cervical cancer 
prevention in older women. Still, while our study suggested that 
it is just as worthwhile to continue to screen older as younger 
women after several negative smears, it showed that, in fact, 
the incidence of cancer among both is low. Further research 
should clarify whether women with well-documented adequate 
and negative screening histories could be offered less intensive 
screening schedules. 
4. What is the negative predictive value of the 
HPV test compared to the Pap smear in primary 
screening?
In a European study, the incidence of CIN 3+ six years after a 
negative HPV test was lower than three years after a negative 
smear. If in the Netherlands the HPV test would be used in pri-
mary screening, the screening interval could be safely prolonged 
to more than the current 5 years. 
These results are in line with the published long-term out-
comes of randomized trials from the Netherlands98 and Swe-
den.99 A longer screening interval could provide some coun-
terweight to the (currently still) higher price of the HPV test 
compared to the Pap smear, and to an expected increase in fol-
low-up testing. The latter may occur because the HPV-positivity 
rates are generally higher than the smear positivity rates (by a 
factor 2 to 4).98, 99 
Any new increase in test positivity would have to be bal-
anced with the public health benefi t measured in a lower inci-
dence of cervical cancer in women with a negative HPV test than 
it is presently the case. This data is not yet available. The indi-
vidual trials pooled into the European study, as well as the cur-
rently on-going randomised trials were powered to high grade 
CIN (CIN 2+ or CIN 3+) as the endpoint. This was recommended 
as the best feasible endpoint for establishing the effi cacy of 
Table 8-1. The estimated number of women referred to a gynaecologist due to cervical abnormalities (directly or after 
positive triage of low-grade abnormal smears), per 100,000 women at risk, per year.23, 93, 128
Estimated number of women 
referred (×1,000)†
Population at risk aged 20-84 
(×1,000)
Estimated number of women 
referred per 100,000 population 
at risk
Year A B C=A/B
1990 8 5,097 152
1991 8 5,150 148
1992 8 5,199 149
1993 7 5,237 142
1994 8 5,269 150
1995 7 5,288 135
1996 16 5,307 299
1997 12 5,328 231
1998 9 5,354 170
1999 8 5,385 145
2000 7 5,420 128
2001 7 5,459 129
2002 7 5,496 132
†Regardless of the reason for smear-taking. Including women with a direct referral, positive triage of low-grade abnormal smears, or 
early referral.
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new cervical cancer prevention technologies, 
i.e. HPV testing and HPV vaccination.248 For 
modelling studies based on this data, extrapo-
lation from CIN to cancer will need to be made. 
To support such extrapolation, the relative 
risk of cytology-negative HPV-positive CIN, 
i.e. of CIN that would be missed by cytological 
but not HPV screening, should be established. 
Invasive cancer (the true endpoint), on the 
other hand, would require much larger studies. 
Instead, pooling the data from the randomised 
trials46 once it becomes available will allow an 
unbiased estimate of the increase in the pro-
gramme sensitivity from using the HPV test. 
5. What is the optimal use of HPV 
testing in triage of women with a 
persistent low-grade abnormal smear?
By restricting gynaecologic follow-up to the 
HPV-positive women with a persistent low-grade 
abnormal (borderline or mildly dyskaryotic) 
smear, gynaecologic follow-up in the HPV-neg-
ative women is not needed anymore, and pre-
vention of cervical cancer will not be compro-
mised. 
For women with a persistent low-grade 
abnormal smear, the 2006 Dutch pathology 
guidelines recommend immediate HPV testing, 
and an immediate referral to a gynaecologist 
in case the HPV test is positive (Figure 8-1).58 
However, according to these guidelines women 
with a negative HPV test should undergo a sec-
ond combined follow-up test (cytology + HPV) 
12 months later. For these women, the fi nal 
decision on whether they can rejoin regular 
screening or need to be referred, will be made 
only at this point. The complexity of such a 
follow-up process is considerable. In the Eras-
mus MC trial, almost all of the initially HPV-
negative women could rejoin regular screening 
after 12 months.Chapter 6 Moreover, an HPV-
positive test 12 months after an initial HPV-
negative test might merely signal a new HPV infection associ-
ated with a new cervical lesion that will, if at all, only progress 
to cancer in many years.32-34 Nevertheless, a small residual risk 
may exist. In this context, the next regular screening round 
could serve as a safety net, at least for women aged ≤55 years 
who will still be invited to screening.
The impression is, therefore, that the pathology guidelines 
from 2006 are more geared towards protecting the sensitivity 
than the specifi city of the programme. Due to the relatively 
small study size and the relatively short follow-up time in the 
Erasmus MC trial we could not analyse the (relative) effective-
ness of all strategies. Several well-documented factors, e.g. the 
long preinvasive period,32-34 and the higher than 90% sensitivity 
of HPV for detecting underlying high-grade CIN lesions in low-
grade abnormal smears208, 233 support the view that following-up 
women who tested HPV-negative may not bring about consid-
erable clinically relevant benefi ts. This, however, remains to be 
confi rmed by the long-term follow-up studies from randomised 
trials.46 
8.2. The reliability of the PALEBA/PALGA data
In the past decade, the PALEBA/PALGA data has been used as 
the main data source for the national evaluation of the Dutch 
cervical cancer screening programme. Upon retrieval from 
PALGA, the registered information is translated into PALEBA/
PALGA categories. This is done in order to decrease the complex-
ity of the PALGA data in the case of test outcomes, or to make 
an inference on the likely sequence of the tests, which is not 
directly registered in PALGA. This process is described in detail 
elsewhere.83 In order to get insight into how reliable PALEBA/
PALGA is, we compared it with two other data sources: with the 
data from the Dutch Cancer Registry,4 and the data obtained 
from the pathology laboratories of one of the screening regions 
(Region West: the SBBW data, made available by the Leiden 
Cytologic and Pathologic Laboratory). 
Figure 8-1. The new (post-2006)58 pathology guidelines for management of 
women with a second low-grade abnormal smear, and the strategy proposed 
in Chapter 8.
New (post-2006) guidelines (2-stage HPV testing)
Strategy proposed in Chapter 8 (1-stage HPV testing)
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Comparison with the Dutch Cancer Registry data
At present, PALGA is the only national data source relating the 
individual cervical cancer cases with their screening histories. 
Since cancer is principally a pathological diagnosis, most cases 
are registered in PALGA. Only a minority of the cancer cases 
(less than 5%)249 is not based on pathology. PALGA is (one of) 
the main sources of data for the Dutch Cancer Registry (CR). The 
latter is authorised to also access e.g. the individual hospital 
patient data, and is this way able to verify the individual PALGA 
diagnoses. At present, however, there is no link back to PALGA 
with cases accepted as cancer cases in the CR. 
For PALEBA/PALGA, complete histories (including the 
pathologist’s free-text specimen descriptions) were retrieved for 
women with at least suspected cervical cancer registered among 
the Thesaurus-like codes since 1994. The fi nal PALEBA/PALGA 
diagnosis of cervical cancer was based on the best judgement 
of all the codes and the free-text entries for histology. In the 
period 1994-2003 (the last year for which the CR data is cur-
rently available), PALEBA/PALGA contains on average 7% more 
incident cancers than CR: about 10% more up to age 74, and 7% 
fewer at older ages (Table 8-2). By calendar year, this gap was 
neither systematically decreasing nor increasing. Thus, while 
the incidence rates in PALEBA/PALGA by age 74 are somewhat 
too high, the conclusions from analyses presented in this the-
sis (a comparison between two calendar periods in Chapter 3, 
and a comparison between the age groups in Chapter 4) were 
not affected. 
Comparison with the laboratory data from Region West 
(SBBW)
In the SBBW data, covering The Hague, Leiden, Delft, Gouda, 
and the countryside between Rotterdam, Utrecht, Haarlem and 
the North Sea, the size of the target population is based on the 
actual number of invitations sent. The cytology reports of all 
programme smears taken from women in the postal area code of 
the SBBW are sent to SBBW from the 6 regional laboratories. In 
order to obtain information on histological follow-up, the SBBW 
sent the records of women with a follow-up advice to the pathol-
ogy laboratories, and received structured follow-up data includ-
ing pathology reports. In part, the pathologists also use the 
PALGA system for the retrieval of pathology diagnoses, e.g. if 
women are treated in hospitals outside of the region. Because all 
information can be verifi ed, it is estimated that there are, unlike 
in PALEBA/PALGA, virtually no incorrect matches between pri-
mary screening and the follow-up data. 
We compared the two datasets based on several process 
indicators for the programme in 2003 (Table 8-3). The differ-
ence in most screening process indicators (the size of the target 
population, the proportion of positive results, the repeat smear 
compliance and the detection rate of CIN 3+) was very small. 
This indirectly suggests that excluding women with the 0.5% 
most common surnames, as is done in all PALEBA/PALGA studies 
of follow-up, adequately avoids the problem of administrative 
twins. On the other hand, the number of primary programme 
smears in PALEBA/PALGA was 7% lower, and the detection rate 
of CIN 1 was 54% higher. 
The lower number of programme smears in PALEBA/PALGA 
compared to the SBBW data was due to the data from one of the 
regional laboratories not being registered in PALGA. The miss-
ing data is going to be retroactively restored in PALGA, and will 
consequently be retrievable for PALEBA/PALGA. 
The reason for the different estimate of the detection rate 
of CIN 1 is more complex. In PALGA, the (histological) diagnoses 
are registered with Thesaurus-compatible codes. Until recently, 
preinvasive fi ndings could be described with a large number of 
codes. For PALEBA/PALGA, these have to be interpreted (trans-
lated) into CIN diagnoses. Compared with the pathology prac-
tice, PALEBA/PALGA seems to use a broader interpretation of 
CIN 1, one which includes codes of atypia, hyperplasia, dysplasia 
NOS with or without clear resection margins, etc. This assures 
that the smears made shortly after such a diagnosis would be 
interpreted as follow-up rather than primary screening smears, 
as it is more likely that these women remained under follow-up 
by a gynaecologist than rejoined the regular screening sched-
ule. In order to avoid the problems of interpretation, PALGA in 
2007 restricted the number of Thesaurus-compatible codes that 
can describe a CIN lesion. It is expected that as a consequence 
the detection rates from PALEBA/PALGA will decrease and/or 
those from other sources increase, thereby limiting the present 
Table 8-2. The number of incident invasive cancers in PALEBA/PALGA, and in the Dutch Comprehensive Cancer Registries, 
by year and age at diagnosis.4, 93
Year
Age group
<30 30-44 45-59 60-74 ≥75 Total
P CR P CR P CR P CR P CR P CR
1994 37 24 271 257 203 180 166 146 101 109 778 716
1995 43 44 313 293 192 170 156 135 85 85 789 727
1996 36 32 333 286 182 166 145 138 96 98 792 720
1997 42 36 322 279 200 180 153 149 96 91 813 735
1998 38 42 272 278 180 176 142 150 85 103 717 749
1999 35 39 295 290 187 170 125 114 89 90 731 703
2000 22 15 279 265 187 169 140 123 78 108 706 680
2001 28 27 258 244 173 157 111 94 78 82 648 604
2002 33 29 250 234 185 168 135 127 86 86 689 644
2003 24 21 249 223 176 157 105 82 97 101 651 584
PALEBA vs. CR† 109 100 107 100 110 100 110 100 93 100 107 100
P = PALEBA/PALGA, CR: Dutch Comprehensive Cancer Registries. †CR=100. Average for years 1994-2003.
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differences. The actual effects of the change in the registration 
should be observable already on short term. 
Regional vs. national data: advantages and 
disadvantages
Evaluation of the Dutch cervical cancer screening programme 
takes place on the national and the regional level. These two 
levels are complementary. At the regional level, the data on the 
screening programme can be obtained directly from the labora-
tories, whereas additional information on e.g. follow-up can be 
obtained through linkage with PALGA. Strong points of regional 
monitoring are that it is easier to verify the fi nal diagnoses, 
and that it gives the possibility of benchmarking and providing 
feedback to individual laboratories. On the other hand, it misses 
the data necessary for the evaluation of long-term screening 
effectiveness. For example, at the regional level it is at present 
not possible to evaluate non-programme screening, whereas in 
PALEBA/PALGA it is. Next, women may move across the borders 
of a single region, which makes it more diffi cult to determine 
their lifetime screening histories. Also, regional databases are 
underpowered to provide reliable frequency estimates of rare 
events, e.g. the interval cancers. 
8.3. Other techniques and tools for cervical 
cancer prevention
The Pap smear helped reduce cervical cancer mortality,43 but it 
is not perfect.250 The efforts to improve it, and to improve cervi-
cal cancer prevention in general, have led to several other tech-
niques and tools described below. 
Liquid-based (thinlayer, monolayer) cytology, and 
automated screening
Using a conventional Pap smear, a sample of exfoliated cells 
from the cervix uteri is transferred and smeared onto a glass 
and fi xed in order to prevent air-drying which would distort 
cellular detail.251 In this process, errors may occur which may 
cause the smear to be unusable or suboptimal for evaluation. 
This is reduced with liquid-based cytology (LBC; marketed as 
e.g. ThinPrep, AutocytePrep, CytoRich, Cytoscreen, Papspin), in 
which the exfoliated cells are instead rinsed into a vial of fi xa-
tive fl uid.251 LBC is a standard cytological primary test in the 
USA and England,141, 252 where as a consequence the proportion 
of inadequate cytology tests recently halved from almost 10% 
to less than 5%.253 At present, the proportion of 
inadequate quality smears in the Netherlands is 
low (about 1%), and LBC was not considered cost-
effective for the introduction into the Dutch cer-
vical cancer screening programme.142 Even though 
it is not recommended within the screening pro-
gramme, the use of LBC has nevertheless increased 
in the Netherlands.
At present, the cost of LBC is higher than 
that of conventional cytology.231 Several studies 
claimed that this could be balanced by a decreased 
proportion of inadequate samples, and increased 
sensitivity and/or specifi city. Two recent sys-
tematic reviews, however, could not substantiate 
these claims as they found no evidence that LBC 
performs substantially better than the conven-
tional Pap smear.254, 255 The average rate of inad-
equate samples was on average only marginally lower.255 The 
LBC tended to increase the rate of low-grade abnormal cytologic 
results (ASCUS and LSIL).255 No signifi cant improvement in the 
detection of high-grade CIN lesions could be seen.254  
Smears prepared for evaluation are read in pathology labora-
tories. During this labour-intensive process reading errors caus-
ing false-negative results may occur. This has been sought to 
be improved on by automating the reading of smears (e.g. the 
PAPNET, AutoCyte SCREEN, AutoPap 300QC, FocalPoint systems). 
In automated reading of smears, a computer system can either 
separate negative smears not needing manual reading from 
those that do deserve a cytotechnician’s attention, or select the 
abnormal parts of the smear to guide manual reading. 
Also for this system early non-randomized studies showed a 
much-improved screening performance compared to the manual 
reading of slides. A recent randomized study performed within 
the Finnish organized screening programme with high-qual-
ity manually-read cytology also found a (somewhat) improved 
detection of preinvasive lesions (RR=1.1). This moderate effect 
was seen only after 3 years of using automated reading on sev-
eral hundred thousand slides.256 Automatization of smear read-
ing can decrease the costs of screening time considerably, yet 
the additional costs of processing and of equipment tend to neu-
tralize this favourable effect.257 
Even though the studies have so far not shown that either 
the LBC or automated screening perform substantially better 
in terms of improving the achieved standards of conventional 
manually-read cytology, they have some other advantages which 
make them an interesting option to consider for screening in 
the future. For example, the residual liquid of the LBC sample 
can be used for additional HPV testing, which would obviate 
scheduling and taking two separate tests in case the presence of 
an HPV infection would need to be determined. Also, it has been 
shown that both the LBC and automated screening can improve 
the output of cases per smear reader.257, 258 These new methods, 
despite their less favourable cost-effectiveness ratio compared 
to conventional cytology,142 could offer a solution to the Neth-
erlands and other countries where a shortage of cytotechnicians 
is becoming a reality. Should the shortage continue to worsen, 
the drawbacks of these systems (the tendency to fi nd more low-
grade abnormal smears,255, 259 higher costs142) should be prop-
erly addressed before their use becomes widespread. 
Table 8-3. Women invited to screening in 2003: Comparison of the SBBW 
and PALEBA/PALGA data for region West.
SBBW data PALEBA/PALGA 
data for region 
West93
Target population 81,555 81,768
Primary program smears 54,931 50,947
Attendance rate 69% 62%
Repeat smear advice† 1.89% 1.93%
Repeat smear compliance 85% 86%‡
Immediate referral advice 0.35% 0.33%‡
Histoscore: CIN 1 0.07% 0.11%‡
Histoscore: CIN 3+ 0.31% 0.30%‡
†Due to Pap 2/3a1, or inadequate quality. ‡Excluding women with 0.5% most 
common surnames.
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HPV vaccination
The fi nding that cervical cancer cannot occur without an infec-
tion with one of the high-risk types of the Human Papilloma-
virus (HPV) started research into primary prevention of cervi-
cal cancer through HPV vaccination. Two vaccines (Gardasil and 
Cervarix) have been approved for market use in e.g. several EU 
countries and the USA. Both of these 1st generation prophy-
lactic vaccines target the two HPV types (16 and 18) that are 
responsible for about 70% of the incident cases worldwide.260, 
261 Currently about fi ve years of available follow-up (in the fre-
quently screened trial participants) estimated the vaccine effi -
cacy against persistent infection with HPV 16 or 18 at 76-100%, 
and against HPV 16 or 18-related CIN 2+ at 90-100%; while the 
potential for long-term cross-protection (i.e., against other 
oncogenic HPV types) may also play a role.262-267 Because the 
highest grade of protection is achieved if women are vaccinated 
before their fi rst infection with HPV 16 or 18,262, 266, 268 the vac-
cine has thus far been approved for use only in girls and very 
young women.269 The trials evaluating the effi cacy of vaccina-
tion in older women are still in progress. Several issues that are 
crucial for an effective implementation of HPV vaccination pro-
grammes, e.g. the duration of the immune response, the rate of 
protection against cervical cancer, the long-term safety profi le, 
etc. are still uncertain.270-272 
HPV vaccination is going to play an increasingly impor-
tant role in cervical cancer prevention. In the Netherlands, the 
Health Council in 2008 recommended to introduce this vaccine 
into the National Immunisation Programme for 12-year old girls 
despite its poorer cost-effectiveness compared to the current 
screening programme.270 Even if vaccination will be introduced, 
it will not be able to completely replace screening. The imple-
mentation of the new combination of screening and vaccination 
will need to be properly planned, monitored and evaluated.273 
Despite vaccination, screening will continue to play a role 
in cervical cancer prevention for two reasons. First, the vaccine 
should preferably be administered before the sexual debut, i.e. 
in early teenage years. The risk for cervical cancer for the major-
ity of women already targeted by the screening programmes, and 
younger women who will be too old to be targeted by vaccina-
tion, will thus not be affected by the vaccine. Second, the vaccine 
does not protect against all high-risk HPV types. It is estimated 
that in Europe and Northern America the maximum achievable 
decrease in cervical cancer incidence through HPV vaccination is 
about 70%.261 This maximum achievable effectiveness is depen-
dent on high vaccination coverage.274 There are other (theoreti-
cally possible) threats for the effectiveness of the vaccine. One 
is type replacement, a phenomenon whereby the niche of the 
vaccine-eradicated HPV-types could become re-populated with 
other oncogenic HPV types. Another is the development of onco-
genic viral escape mutants, which would not be preventable by 
the vaccine. The likelihood of these phenomena to occur is con-
sidered to be low,273 but will need to be monitored. 
It is not yet determined what would be the optimal screen-
ing policy within the context of an effective HPV vaccination. 
Maintaining an equally intensive screening programme for the 
vaccinated women, however, would be very expensive and much 
less cost-effective than the current screening in non-vaccinated 
women. First, by the time the vaccinated women will reach 
screening age, their background risk for cervical cancer will 
be substantially lower than in unvaccinated cohorts. Second, 
the characteristics of cytology and HPV screening in vaccinated 
women may differ from screening in non-vaccinated women. 
HPV and cytology positivity in vaccinated women will decrease, 
but for HPV more so than for cytology.275 As a consequence, in 
vaccinated women the specifi city of HPV would improve com-
pared to that observed in the non-vaccinated women. Moreover, 
in the context of a decreased PPV for high-grade lesions, the 
quality of smear-reading may deteriorate and consequently the 
sensitivity or specifi city of cytology may decrease.276 In case a 
considerable proportion of the population will be vaccinated, 
more research will need to be done into the optimal combina-
tion with screening.
For monitoring and evaluation, the data on all HPV tests as 
well as on HPV vaccinations should be registered in such a way 
that it could be readily linked to the cervical cytology and his-
tology (PALGA) or other relevant registries.277 In this respect it 
is a positive development that all HPV tests and their results will 
be routinely registered in PALGA. This is possible because (most 
of) the HPV tests are performed in pathology laboratories. For 
HPV vaccination, there is no registration set up yet, but should 
be established as soon as possible. 
8.5. Conclusions and recommendations
1. The changes in the protocols and guidelines of the Dutch 
cervical cancer screening programme since 1996 helped to 
increase the coverage and to decrease the negative side 
effects of screening. 
2. The shift of 80% of low-grade abnormal smears towards 
negative smears after 1996 did not measurably decrease 
the Pap smear sensitivity. 
3. It is not consistent to stop screening women after they 
have had several consecutive negative smears by age 50, 
while not also relaxing the screening policy of similar 
younger women.
4. If the HPV test would replace the Pap smear in primary 
screening, the screening interval could be lengthened to 
more than the current 5 years.
5. Releasing HPV-negative women with a persistent low-grade 
abnormal smear to regular screening would reduce over-
treatment without markedly decreasing the sensitivity of 
the screening programme. 
6. Because cervical cancer prevention may undergo substan-
tial changes in the near future, monitoring remains impor-
tant. 
7. Registration of HPV tests and HPV vaccination should be 
implemented either within PALGA, or readily linkable to 
PALGA at the level of an individual woman.
8. The expected increase in the screen-positivity rate in case 
of HPV testing should be critically assessed against the 
increase in the sensitivity. 
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8.6. Appendix: Trends in screening process indicators
Table 8-A1. 5-year coverage rates (in % of the population at risk)† with Pap smears in women aged 15-84 in the 
Netherlands in the period 1994-2006.23, 93, 128
Year
Age group
15-
19
20-
24
25-
29
30-
34
35-
39
40-
44
45-
49
50-
54
55-
59
60-
64
65-
69
70-
74
75-
79
80-
84
20-
29
30-
64
65-
84
1994 2 15 37 54 81 84 83 82 59 23 15 11 8 7 27 69 11
1995 1 14 36 53 82 83 83 81 59 25 15 11 8 7 26 69 11
1996 1 13 33 58 81 84 84 81 68 33 15 11 8 6 24 72 11
1997 1 11 29 64 81 85 85 82 76 45 15 11 8 6 21 76 11
1998 1 9 25 68 81 85 87 83 80 57 15 11 8 6 18 78 11
1999 1 8 21 71 82 85 86 84 81 70 15 10 8 6 15 80 10
2000 1 7 17 72 82 83 86 85 81 79 15 10 7 6 12 81 10
2001 1 6 15 71 80 82 84 85 79 77 15 9 7 6 11 80 10
2002 1 6 13 69 78 81 83 83 79 75 14 8 6 5 10 78 9
2003 1 5 12 68 77 81 82 81 80 74 14 8 6 5 9 78 9
2004 1 6 12 69 77 81 81 81 80 75 14 8 6 5 9 78 8
2005 1 6 12 69 78 81 81 81 79 76 15 8 6 5 9 78 9
2006 1 6 12 70 78 81 82 82 79 76 13 8 6 5 9 78 9
Shaded columns represent the post-1996 target age group. †Population at risk is the number of resident women on 1st January of 
the analysed year, excluding the estimated number of women who have undergone a hysterectomy. The estimated proportion of 
women with 0.5% most common surnames is excluded (based on the number of smears registered in PALGA in all vs. those women 
with 0.5% most common surnames; assuming that the commonness of surnames and screening behaviour are not correlated). 
Table 8-A2. The participation rates in the Dutch cervical cancer screening programme, per age at invitation and year in the 
period 1996-2006.23, 93, 128
Year
Age at invitation
30 35 40 45 50 55 60 Total
1996 34% 38% 31% 16% 34% 28% 38% 31%
1997 40% 45% 40% 43% 39% 35% 43% 41%
1998 46% 51% 54% 52% 46% 50% 47% 50%
1999 51% 56% 61% 59% 55% 59% 53% 56%
2000 52% 60% 68% 65% 62% 66% 59% 61%
2001 51% 61% 67% 67% 64% 66% 64% 62%
2002 51% 62% 68% 69% 69% 67% 65% 64%
2003 52% 63% 69% 70% 71% 69% 66% 66%
2004 52% 61% 69% 70% 71% 70% 67% 66%
2005 52% 61% 68% 70% 71% 69% 68% 65%
2006 53% 61% 68% 70% 71% 70% 69% 66%
Excluding the estimated number of women who have undergone hysterectomy. Before 2000, 14%-31% of smears had no reason for 
smear-taking registered (Table 8-A5), thereby the participation rate is likely underestimated. 
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Table 8-A3. The type of advice given in the screening programme in the period 1990-2006, by screening year.93
Year
Follow-up advice
Total number 
of programme 
smears†
Next 
screening 
round 
(Pap 1)
Repeat 
smear 
(Ecc-)
Repeat 
smear 
(Pap 0)
Follow-up 
smear‡
Immediate 
referral§
Any follow-
up advice
1990 131,372 76.6% 10.3% 1.6% 11.2% 0.3% 23.4%
1991 137,996 78.8% 9.1% 1.1% 10.7% 0.3% 21.2%
1992 152,463 78.9% 8.7% 1.2% 11.0% 0.3% 21.1%
1993 156,869 79.4% 8.0% 1.1% 11.1% 0.3% 20.6%
1994 162,537 81.1% 7.3% 1.3% 10.0% 0.3% 18.9%
1995 166,916 80.7% 7.8% 1.5% 9.8% 0.2% 19.3%
1996 218,807 84.8% 8.2% 1.0% 5.4% 0.6% 15.2%
1997 287,170 87.0% 7.8% 0.9% 3.7% 0.6% 13.0%
1998 351,675 88.7% 7.4% 0.9% 2.4% 0.6% 11.3%
1999 409,547 89.2% 7.2% 0.8% 2.1% 0.6% 10.8%
2000 442,767 89.0% 7.3% 1.0% 2.0% 0.6% 11.0%
2001 467,256 88.6% 7.7% 1.0% 2.1% 0.6% 11.4%
2002 481,483 96.4% n.a. 1.0% 2.0% 0.6% 3.6%
2003 490,780 96.7% n.a. 1.0% 1.8% 0.5% 3.3%
2004 497,023 96.6% n.a. 1.1% 1.7% 0.6% 3.4%
2005 488,510 96.5% n.a. 1.1% 1.9% 0.6% 3.5%
2006 507,536 96.0% n.a. 1.4% 2.0% 0.6% 4.0%
Ecc-=negative smears without endocervical cells. n.a.=not applicable (Ecc- smears not followed-up between 2002 and 2006). 
†Primary smears labelled as due to the screening programme, registered from 1st January of the analysed year until 31st March of 
the following year, for the programme-eligible birth cohorts. ‡1990-1995: Pap 2, Pap 3a1 and Pap 3a2; 1996-2006: Pap2 and Pap 
3a1. §1990-1995: Pap 3b+; 1996-2006: Pap 3a2+. 
Table 8-A4. Compliance with follow-up† in the screening programme, by type of recommendation and screening year.93,‡
Year
Type of follow-up smear advice
Immediate referral Follow-up smear Inadequate quality
1990 96% 83% 80%
1991 96% 85% 84%
1992 96% 83% 84%
1993 95% 76% 76%
1994 98% 78% 84%
1995 98% 78% 86%
1996 96% 70% 80%
1997 96% 69% 80%
1998 97% 85% 84%
1999 97% 90% 84%
2000 97% 90% 85%
2001 97% 90% 85%
2002 96% 91% 87%
Excluding women with 0.5% most common surnames. †At least cytology within 4 years of the primary smear. ‡Abnormal smears 
taken between 1st January of the analysed year until 31st March of the following year, for the programme-eligible birth cohorts.
Matejka BW.indd   59 31-10-2008   15:28:09
60
Table 8-A5. The total number of smears made (all ages),† and the reason for smear-taking (in % of the total) per calendar 
year in the period 1990-2006.93
Total number 
of smears
Reason for smear-taking (%)
Primary smears Secondary 
smears
Year
Screening 
programme
Opportunistic 
screening
Medical 
complaints
Unknown
1990 964,585 21% 7% 4% 41% 27%
1991 964,641 23% 7% 4% 40% 26%
1992 956,045 24% 8% 4% 39% 26%
1993 937,055 23% 7% 5% 39% 26%
1994 990,261 23% 6% 7% 39% 25%
1995 971,130 24% 6% 7% 37% 26%
1996 1,073,447 35% 4% 6% 31% 24%
1997 1,086,863 39% 3% 6% 28% 24%
1998 993,357 47% 3% 7% 22% 21%
1999 897,815 54% 3% 10% 14% 19%
2000 830,381 60% 2% 11% 9% 17%
2001 843,022 62% 2% 12% 9% 15%
2002 810,015 66% 3% 14% 9% 9%
2003 797,526 67% 2% 13% 9% 9%
2004 824,046 67% 2% 13% 9% 8%
2005 789,717 68% 2% 13% 8% 8%
2006 807,082 68% 2% 14% 8% 9%
†Adjusted for population growth (20-84 years) relative to 2006.23 
Table 8-A6. The total number of smears made in women aged 20-29, and in % of the total number of smears, per calendar 
year in the period 1990-2006.93
Year Smears at age 20-29 Smears at age 20-29, adj.† Proportion of all smears
1990 150,345 116,658 17%
1991 144,390 112,216 16%
1992 139,161 108,823 16%
1993 129,662 102,940 15%
1994 130,459 105,767 14%
1995 118,856 99,044 13%
1996 108,699 93,091 11%
1997 105,971 93,051 10%
1998 91,431 82,341 10%
1999 82,588 76,611 10%
2000 56,755 54,004 7%
2001 52,269 50,691 6%
2002 46,672 46,017 6%
2003 44,373 44,191 6%
2004 45,853 45,920 6%
2005 45,250 45,327 6%
2006 48,249 48,249 6%
†Adjusted for the growth of the population aged 20-29 (2006=index year).23 
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Summary
From 1996 onwards, new cervical cancer screening protocols 
and guidelines were implemented because the existing screen-
ing practice (the loosely organized programmes and spontane-
ous screening) was far from optimal. The organized programmes 
were changed into one national programme in which women are 
invited at 5-yearly intervals between ages 30 and 60. Smears 
are taken at the general practitioner’s (GP) practice, and are 
free of charge. Screening outside of the programme has been 
discouraged. National guidelines were published for GPs, pathol-
ogists and gynaecologists. The programme is fi nanced by ear-
marked national funds, and implemented by 12 regional screen-
ing organisations. The fi rst part of this thesis presents several 
aspects of the functioning and effectiveness of the programme, 
evaluated recently at the national level. 
In the late 1990’s, it was confi rmed that an infection with 
oncogenic Human Papillomavirus (HPV) is a necessary cause of 
cervical cancer. This spawned interest into both new tools for 
early detection of cervical cancer (HPV test), as well as into 
primary prevention through HPV vaccination. The second part 
of this thesis presents recent work exploring the possibilities of 
using the HPV test in in primary screening, and in triage of low-
grade abnormal smears.
The screening process
In Chapter 2, we analysed the changes in the screening pro-
gramme by 2003 in terms of the coverage, resource use and side 
effects. These indicators give an early signal whether the pro-
gramme is achieving its goal of mortality reduction, and help 
assess the screening-induced burden on screened individuals. 
We showed that there have been considerable improvements in 
the screening programme on both counts. First, the 5-year cov-
erage rate is now close to 80%. Since 1994, it increased espe-
cially in the added target age groups (30-34 and 54-64 years). 
Second, the new screening protocols and guidelines brought 
about a considerable decrease in the resource use (a 20% over-
all decrease in smears made per year, especially among women 
below 30 years), and a decrease in screening-induced side effects 
(an approximately 80% decrease in the programme smear posi-
tivity rate, and much quicker decision-making for women with 
positive screening smears). 
The broadened defi nition of a negative smear
A change in the classifi cation of infl ammation from abnormal 
to normal caused an approximately 70% overall decrease in the 
number of women with a follow-up advice due to a positive 
smear. In Chapter 3, we showed that this was not associated 
with a measurable decrease in smear sensitivity: within 6 years 
of a negative smear, the incidence of cervical cancer after a 
negative smear was similar in the periods before and after 1996. 
This suggests that infl ammation (without concurrent signs of 
dysplasia) is not a risk factor for cervical cancer. 
Screening after several consecutive negative smears by 
age 50
Fewer CIN lesions are detected in women who had several neg-
ative smears by age 50 compared to similar younger women. 
This has been an argument calling to cease screening in these 
women. Using CIN data in age comparisons, however, is prob-
lematic because the progression rate of CIN lesions to cancer 
increases with age. In Chapter 4, we showed that the incidence 
of cancer after the third consecutive negative smear around age 
50 is the same as after the third consecutive negative smear 
in younger women. This fi nding showed that it would not be 
consistent to stop screening in women with several consecu-
tive negative smears at age 50, while not relaxing the screening 
policy for similar younger women.
HPV testing in primary screening
In order to assess the differences in their negative predictive 
value, we compared the incidence rates of CIN 3+ after a nega-
tive HPV test and a negative Pap smear. In Chapter 5, we ana-
lysed a large data set composed of seven recently fi nished Euro-
pean trials, in which women were screened with the Pap smear 
and the HPV test, and thereafter followed for several years. We 
found that within 6 years of a negative HPV test fewer women 
develop a CIN 3+ lesion than within 3 years of a negative Pap 
smear. We conclude that in case the HPV test would substitute 
the Pap smear as the primary test, the screening interval could 
be safely prolonged to more than the current 5 years. However, 
the advantages of the HPV test over the Pap smear in terms of 
higher sensitivity will have to be balanced with the disadvan-
tages in terms of lower specifi city and possibly higher costs. 
HPV testing in triaging of women with persistent low-
grade abnormal smears
The standard follow-up recommendation for women with a per-
sistent low-grade abnormal smear was a referral to a gynaecolo-
gist. Because the majority (80%) of these women do not have a 
high-grade CIN (CIN 2+) lesion, a signifi cant burden was induced 
on women and the health care. In Chapter 6 and Chapter 7, 
we explored whether instead of the standard recommendation a 
high-risk selection could be made based on the HPV test. In the 
trial, almost all high-grade CIN lesions were found in HPV-posi-
tive women, whereas the negative predictive value of a negative 
HPV test was close to 100%. Compared to the standard recom-
mendation, triage by HPV testing resulted in a decrease in the 
total costs, and an alleviation of the screening burden. In view 
of simplicity for both physicians and women, it is preferable to 
combine the HPV test with the fi rst follow-up smear. 
Conclusion
The implementation of the new guidelines and protocols has 
improved the Dutch cervical cancer screening programme con-
siderably. The coverage rate increased in the previously under-
screened age groups, whereas the abnormality rate decreased. 
In the future, the programme may change due to newer early 
detection techniques and tools for cancer prevention. HPV 
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testing seems promising in triage of low-grade abnormal smears. 
For primary screening, the balance between a higher sensitivity 
but lower specifi city and higher costs of the HPV test compared 
to the Pap smear will have to be assessed in a cost-effectiveness 
analysis. 
Samenvatting
In 1996 zijn nieuwe protocollen en richtlijnen geïmplement-
eerd voor de screening op baarmoederhalskanker. De bestaande 
screeningpraktijk was destijds verre van optimal. De georgani-
seerde screening werd nationaal gestandaardiseerd tot een bev-
olkingsonderzoek waarin vrouwen in de leeftijdsgroep 30-60 jaar 
iedere 5 jaar werden uitgenodigd om bij de huisarts een (gratis) 
uitstrijkje te laten maken. Spontane screening werd ontmoedigd. 
Voor huisartsen, pathologen en gynaecologen werden nieuwe 
nationale screeningsrichtlijnen opgezet. Het bevolkingsonder-
zoek werd gefi nancierd uit speciale fondsen door de overheid 
en geïmplementeerd door 12 regionale screeningsorganisaties. 
In het eerste gedeelte van dit proefschrift worden verschillende 
aspecten gepresenteerd met betrekking tot het functioneren en 
de effectiviteit van het nieuwe bevolkingsonderzoek dat recent 
op nationaal niveau is geëvalueerd. 
Eind jaren 90 werd bekend dat besmetting met het Humaan 
Papillomavirus (HPV) een voorwaarde vormt voor het ontstaan 
van baarmoederhalskanker. Dit bracht interesse naar voren 
voor de ontwikkeling van zowel nieuwe methoden van vroege 
opsporing van baarmoederhalskanker als voor primaire preven-
tie via vaccinatie tegen HPV. In het tweede gedeelte van dit 
proefschrift wordt recent werk gepresenteerd waarin de mogeli-
jkheden worden onderzocht van het gebruik van HPV testen 
bij primaire screening en bij triage van licht afwijkende uit-
strijkjes.
Het screeningsproces
In Hoofdstuk 2 wordt het bevolkingsonderzoek van 2003 
geëvalueerd op de indicatoren: bereik, inzet van middelen (aan-
tal benodigde uitstrijkjes) en neveneffecten. Deze indicatoren 
geven een vroeg signaal af of het screeningsprogramma sterf-
tereductie bereikt en hoe groot de belasting voor de doelgroep 
is. Op beide punten zijn forse verbeteringen zichtbaar ten opz-
ichte van de situatie voor 1996. Ten eerste is het 5-jaars bereik 
nagenoeg 80% geworden. Sinds 1994 stijgt de dekking met name 
in de toegevoegde doelgroep (30-34 jaar en 54-64 jaar). In de 
tweede plaats is dankzij de nieuwe richtlijnen het middelenge-
bruik van screening naar baarmoederhalskanker gedaald (er 
worden jaarlijks ongeveer 20% minder preventieve uitstrijkjes 
gemaakt) en de ongewenste neveneffecten van screening naar 
baarmoederhalskanker zijn verminderd (80% minder fout posi-
tieve uitslagen en een sneller vervolgtraject voor vrouwen met 
een afwijkend uitstrijkje).
De bredere defi nitie van een negatief uitstrijkje
Een verandering in de classifi catie van ontstekingsverschi-
jnselen van afwijkend naar normaal leidde tot 70% afname van 
het aantal vrouwen dat bij het bevolkingsonderzoek een advies 
voor een herhalingsuitstrijkje kreeg. In Hoofdstuk 3 laten we 
zien dat naar aanleiding hiervan de sensitiviteit van het uitstri-
jkje niet verminderde: de incidentie van baarmoederhalskanker 
binnen 6 jaar na een negatief uitstrijkje was gelijk in de periode 
voor en na 1996. Dit geeft aan dat ontstekingsverschijnselen 
(zonder aanwezige kenmerken van dysplasie) geen risicofactor 
zijn voor baarmoederhalskanker.
Screening na een aantal opeenvolgende negatieve 
uitstrijkjes op 50-jarige leeftijd
In vergelijking met vergelijkbaar gescreende jongere vrouwen 
worden er minder CIN laesies gevonden bij vrouwen die rond hun 
50ste een screeningsgeschiedenis van meerdere achtereenvol-
gende negatieve uitstrijkjes hebben gehad. Dit is een argument 
om screening bij deze vrouwen te stoppen. Het gebruik van data 
over CIN bij vergelijkingen tussen leeftijdsgroepen is problema-
tisch omdat de kans dat CIN progressief is toeneemt met het 
stijgen van de leeftijd. In Hoofdstuk 4 laten we zien dat de 
incidentie van baarmoederhalskanker na het derde achtereen-
volgende negatieve uitstrijkje rond de leeftijd van 50 identiek is 
aan de kans op kanker na drie negatieve uitstrijkjes bij jongere 
vrouwen. Deze bevinding geeft aan dat het niet consequent is 
om bij vrouwen rond de 50 te stoppen met screening na drie 
negatieve uitstrijkjes en niet bij vergelijkbare jongere vrouwen 
het screeningsbeleid te versoepelen.
HPV testen in primaire screening
Om het verschil in de negatief voorspellende waarde te bepalen 
hebben we de incidentie van CIN3+ na een negatieve HPV test 
en na een negatief uitstrijkje met elkaar vergeleken. In Hoofd-
stuk 5 hebben we een grote dataset geanalyseerd bestaande 
uit 7 recent afgeronde Europese trials, waarin vrouwen werden 
gescreend met zowel een uitstrijkje als een HPV test en vervol-
gens verschillende jaren werden gevolgd. We vonden dat binnen 
6 jaar na een negatieve HPV test minder vrouwen een CIN 3+ lae-
sie ontwikkelden dan binnen 3 jaar na een negatief uitstrijkje. 
We concluderen dat in het geval dat de HPV test in plaats van 
het uitstrijkje als primaire test gebruikt zou worden, het screen-
ingsinterval langer zou kunnen worden dan de huidige 5 jaar. 
Desalniettemin moeten de voordelen van de HPV test in vergeli-
jking met het uitstrijkje op het gebied van hogere sensitiviteit 
zorgvuldig worden afgewogen tegen de nadelen waaronder een 
lagere specifi citeit en hogere kosten.
HPV testen bij triage van vrouwen met persistente licht 
afwijkende uitstrijkjes
Het gebruikelijke follow-up advies voor vrouwen met persis-
tente licht afwijkende uitstrijkjes was een verwijzing naar de 
gynaecoloog. Omdat de meerderheid (80%) van deze vrouwen 
geen CIN2+ heeft is dit een behoorlijke belasting voor de betref-
fende vrouwen en voor de gezondheidszorg. In Hoofdstuk 6 en 
Hoofdstuk 7 hebben we onderzocht of het gebruikelijke fol-
low-up advies kan worden vervangen door een risicoselectie te 
maken op basis van de HPV test. In de trial werden nagenoeg 
alle vrouwen met CIN2+ ook positief gediagnosticeerd op basis 
van de HPV test terwijl de negatief voorspellende waarde dicht 
bij de 100% lag. Vergeleken met de standaard richtlijn result-
eert triage met HPV tests in een afname van de totale kosten en 
een vermindering van de belasting voor de betreffende vrouwen. 
Vanuit het oogpunt van gemak voor zowel vrouwen als artsen is 
een combinatie van een uitstrijkje en een HPV test bij het eerste 
herhalingsuitstrijkje aan te bevelen.
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Conclusie
De implementatie van de nieuwe richtlijnen en protocollen heb-
ben de praktijk van screening op baarmoederhalskanker in Ned-
erland sterk verbeterd. Het bereik is toegenomen binnen de 
voorheen ongescreende leeftijdsgroepen, terwijl het percent-
age afwijkende uitstrijkjes sterk daalde. In de toekomst kan het 
bevolkingsonderzoek veranderen door het gebruik van nieuwe 
preventie- en opsporingstechnieken. HPV testen lijken veel-
belovend bij de triage van licht afwijkende uitslagen van het 
uitstrijkje. Voor primaire screening moet de balans tussen een 
hogere sensitiviteit maar een lagere specifi citeit en hogere kos-
ten van de HPV test in vergelijking met het uitstrijkje onder-
zocht worden in een kosten-effectiviteitsstudie.
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